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1 INTRODUCTION 
1.1 Cancer chemotherapy 
In Germany, approximately 470,000 people are diagnosed with cancer each year [1]. After 
cardiovascular diseases, cancer is the second most cause of death in German population [2]. 
In females breast cancer followed by colon and lung cancer and in males prostate, colon and 
lung cancer are most frequent. Considering statistics standardized by age, cancer prevalence 
has been constant over the last ten years with a slight decrease in mortality rate, which is 
probably due to new developments in cancer treatment [1].  
Treatment of cancer is based on surgery and radiation as well as on antineoplastic drugs. The 
term ‘antineoplastic drug’ traditionally comprised mainly chemotherapeutic drugs but has 
been expanded by new classes of drugs such as monoclonal antibodies, tyrosine kinase 
inhibitors and drugs modulating hormone metabolism. Recently developed drugs, which are 
often directed against cancer-specific targets and are thus called ‘targeted drugs’ are, 
however, frequently used as either ‘add-on’ therapy to long-time established drugs or drug 
combinations or after failure of established drugs. Hence drugs from the last century still play 
an important role in the current treatment of cancer and development of effective drug 
combinations is still the aim of research [3,4]. To optimize therapy and to find drug 
combinations with not only additive but synergistic effects, the understanding of the 
molecular way of action and mechanisms of resistance to individual drugs as well as their 
interaction in combination therapies are of great value. 
This project focused on platinum complexes, a class of chemotherapeutics used in the 
treatment of solid malignancies and on mechanisms involved in cellular resistance towards 
these drugs. 
1.2 Platinum complexes 
The platinum complex first introduced in therapy was cisplatin, a square planar complex with 
platinum(II) as central atom, which was approved by the Food and Drug Administration in 
the United States in 1978. It is used in chemotherapy regimens for the treatment of testicular 
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and head and neck cancer, for example [5]. Being successful in the treatment of certain tumor 
types, cisplatin therapy is limited by severe adverse events, such as nephrotoxicity and 
neurotoxicity, and resistance of tumors, either intrinsic or acquired during therapy. Hence 
after the approval of cisplatin the development of further platinum complexes moved on, 
resulting in the approval of carboplatin in the 1980s. Carboplatin is effective in the same 
tumor types as cisplatin but shows a more tolerable side effect profile and has replaced 
cisplatin in the treatment of ovarian tumors and of non-small cell lung cancer as standard 
treatment. Its side effect profile differs from cisplatin as not nephrotoxicity and neurotoxicity 
are but myelosuppression is the major adverse event. In the 1990s a further platinum complex, 
oxaliplatin, was introduced. Oxaliplatin can be used in the treatment of tumors which are 
intrinsically resistant to cisplatin and carboplatin, such as colorectal cancer [6]. The most 
common toxicity associated with oxaliplatin treatment is peripheral neuropathy [7]. The 
chemical structure of the platinum complexes is shown in Fig. 1-1. 
   
Fig. 1-1 Platinum complexes used in cancer therapy: cisplatin (cis-diamminedichloro-
 platinum(II)), carboplatin (cis-diammine(cyclobutane-1,1-dicarboxylate-O,O') 
 platinum(II)) and oxaliplatin ([(1R,2R)-cyclohexane-1,2- diamine](ethanedioato-O,O') 
 platinum(II)) (from left to right). 
Further platinum complexes are only approved in individual countries (e.g. nedaplatin in 
Japan, lobaplatin in China, heptaplatin in the Republic of Korea) and thus were not considered 
in this project. Research on new platinum complexes is ongoing aiming for the development 
of substances with superior side effect profiles and substances overcoming resistance [8]. 
1.2.1 Mechanism of action 
Uptake and activation 
The mechanism of cellular uptake of platinum complexes has not been elucidated completely. 
Passive diffusion, uptake by gated channels, or active transporters such as copper 
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transporter 1 (CTR1) and organic cation transporters (OCT) 1 and 2 are described and a 
combination of diverse mechanisms is probable [9]. 
Inside the cell, platinum complexes undergo aquation by ligand exchange. In case of cisplatin 
one or both chlorido ligands are replaced by water molecules resulting in more reactive 
complexes [6,7,10]. In carboplatin and oxaliplatin the leaving groups, cyclobutane-1,1-
dicarboxylate or oxalate, respectively, are likely to be substituted first by chlorido ligands and 
then by water ligands [7]. 
DNA platination 
The reactive aquated species bind to various intracellular structures, but with respect to 
cytotoxicity nuclear DNA is the most important target [10]. Platinum complexes form 
covalent bonds with the N7 of the purine bases adenine and guanine primarily resulting in the 
generation of monofunctional and bifunctional adducts, the latter comprising intrastrand and 
interstrand crosslinks (Fig. 1-2). In case of cisplatin, intrastrand crosslinks are described to be 
most prevalent (involvement of two guanines: 60 to 65%, involvement of adenine and 
guanine: 20 to 25%, involvement of two guanines with another base in between: 2% of all 
adducts); interstrand crosslinks and monofunctional adducts are less frequent (each with 2% 
of all adducts) [6]. 
The platinum-DNA adducts formed by carboplatin are similar to those formed by cisplatin. 
The adduct formation is, however, slower and the amount of carboplatin needed to yield the 
same number of adducts is higher [6]. Oxaliplatin forms similar adducts, with the difference 
that oxaliplatin-DNA lesions contain a [Pt(trans-R,R-diaminocyclohexane)]
2+
 rather than a 
[Pt(NH3)2]
2+
 group. Hence the structural changes on DNA resulting from oxaliplatin binding 
on the one hand and cisplatin or carboplatin binding on the other hand are not the same, and 
therefore different cellular mechanisms are activated to cope with the platinum-DNA 
adducts [11]. On account of this it can be explained that DNA breaks produced by oxaliplatin 
are commensurate to those produced by cisplatin although the total amount of 
oxaliplatin-DNA adducts is significantly lower compared to cisplatin of equimolar 
concentrations [7,12-14]. 
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Monofunctional adducts Bifunctional adducts 
 
Intrastrand crosslinks Interstrand crosslinks 
 
 
Fig. 1-2 Platinum-DNA adducts as described for cisplatin (A: adenosine, G: guanosine, N: any 
 nucleoside) (modified from [7]). 
Cellular reaction 
Once platinum-DNA adducts are formed, cellular response processes are induced and result in 
either repair of DNA and cell survival, or apoptosis. The fate of the cell depends on the 
intensity of the signals generated and the crosstalk between cellular processes involved, which 
can be cell-type specific and either lead to sensitivity or resistance to all or single platinum 
complexes (for platinum resistance see chapter 1.3) [15]. There is evidence for different 
signaling cascades activated by cisplatin and carboplatin compared to oxaliplatin [7]. One 
signaling pathway involved in cytotoxicity of all platinum complexes used is the mitogen-
activated protein kinase (MAPK) pathway which participates in regulating cell proliferation, 
differentiation, cell survival and apoptosis [10].  
As described before, after damage recognition cellular survival processes can be initiated. 
Survival is triggered by DNA repair or increased tolerance to platinum-DNA adducts. The 
nucleotide excision repair (NER) is the major pathway involved in repair of platinum-DNA 
adducts and lesions induced by platinum complexes. Platinum-DNA adducts formed by 
cisplatin and carboplatin are also recognized by mismatch repair (MMR), but their repair is 
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not successful and results in apoptosis. Due to the different steric properties, oxaliplatin-DNA 
adducts are not detected by the MMR [16].  
Instead of repairing platinum-DNA adducts, cells can replicate DNA bypassing the adducts 
without gaps in the new strand by so-called replicative bypass. Hence replicative bypass 
increases cellular tolerance to platinum-DNA adducts. In the context of replicative bypass 
high mobility group (HMG) proteins have been reported to be of importance for cytotoxic 
action as they bind to intrastrand crosslinks and prevent replicative bypass, but also NER and 
binding of transcription factors [7,17]. Oxaliplatin-DNA adducts, however, have been 
discussed to be poor substrates of replication enzymes involved in replicative bypass [16].  
As damage recognition results in multiple cellular processes, diverse ways of apoptosis have 
been suggested and involvement of tumor suppressor protein p53, MAPK pathways, the 
Fas/Fas ligand signaling complex (activation of caspase 8 and caspase 3), mitochondrial 
cytochrome-c release (activation of caspase 9 and caspase 3), a caspase 3 independent 
apoptotic pathway or defective apoptotic pathways have been discussed [15,18]. Besides 
apoptosis, cells were also described to undergo necrosis when DNA is massively damaged 
and poly(ADP-ribose)polymerase (PARP) proteins have been induced [10,19]. 
In this chapter presumably the main intracellular target of platinum complexes, genomic 
DNA, was discussed. Since only a small proportion of intracellular platinum binds to nuclear 
DNA, further processes influenced by platinum complexes inside the cell need to be taken 
into consideration [20]. 
1.3 Platinum resistance 
Besides toxicity, acquired or intrinsic drug resistance is the main obstacle in cancer 
chemotherapy using platinum complexes. Resistance to platinum complexes is not caused by 
a single cellular process or alteration but derives from multiple interacting factors. 
Considering the formation of platinum-DNA adducts as main target for the mechanism of 
action, resistance to platinum complexes can be structured in pre-target, on-target, post-target 
and off target-resistance [5]. 
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1.3.1 Pre-target resistance 
Pre-target resistance involves processes resulting in reduced cellular platinum accumulation, 
through reduced uptake and/or increased efflux and in increased inactivation of platinum 
complexes.  
It is by now accepted that besides passive diffusion copper transporters and further 
transporters are involved in platinum uptake and efflux and hence contribute to reduced 
platinum accumulation found in resistant cells. The copper transporter CTR1 plays a role in 
the uptake of platinum complexes and CTR1-deficient cells were found to be cisplatin-
resistant [18]. Regarding increased efflux, the copper-transporting P-type adenosine 
triphosphatases ATP7A and ATP7B seem to be involved [18,21]. Multidrug 
resistance-associated proteins (MRP) are also discussed to play a role in platinum resistance 
as they are supposed to contribute to increased efflux. More details on MRP and the relevance 
of MRP for platinum resistance are described in chapters 1.5 and 1.6.  
Cellular thiols have also been associated with pre-target resistance. Glutathione (GSH) is 
likely to contribute to platinum resistance by binding and inactivating platinum complexes 
and reducing platinum-induced oxidative stress [18]. Besides GSH, the rate-limiting enzyme 
in intracellular GSH synthesis, γ-glutamylcysteine synthetase (γGCS), and the enzyme 
catalyzing reactions of GSH with substrates, glutathione S-transferase (GST), have been 
suggested to be involved in platinum resistance [5]. GSH and related enzymes and their role 
in platinum resistance are portrayed in chapters 1.4 and 1.6. In some studies also 
metallothioneins have been implicated to contribute to platinum resistance, presumably by 
drug binding as well. Metallothioneins are rich in thiol-containing cysteine proteins and are 
involved in zinc homeostasis [18]. 
1.3.2 On-target resistance 
There is evidence that the level of cisplatin-DNA adducts correlates with the cytotoxicity of 
the drug [15]; on-target resistance directly relates to platinum-DNA adducts and involves 
increased repair of but also increased tolerance to platinum-DNA adducts.  
Overexpression of components of nucleotide excision repair (NER) results in increased repair 
of platinum-DNA adducts and platinum resistance. Up to now, in vitro studies support the 
contribution of various DNA polymerases, topoisomerase II and homologous recombination 
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repair but clinical evidence proving their relevance for platinum resistance is lacking [18]. 
DNA mismatch repair (MMR) processing of platinum-DNA adducts and failure of repair 
result in apoptosis and thus contribute to platinum sensitivity. Cells with deficiency in MMR 
proteins show resistance against cisplatin and carboplatin due to increased tolerance to 
platinum-DNA adducts and reduced apoptosis [18]. The MMR system is assumed to account 
for differences in the mechanism of action of cisplatin/carboplatin and oxaliplatin. As 
oxaliplatin-DNA adducts are not detected by the MMR system, MMR deficiency does not 
alter cellular sensitivity to oxaliplatin [7]. 
1.3.3 Post-target resistance 
Post-target resistance comprises cellular properties which prevent cells from undergoing 
apoptosis and result in survival. In platinum resistance the apoptotic response resulting from 
the formation of platinum-DNA adducts is reduced. In this context the role of genes 
regulating DNA damage, apoptosis and survival signaling are discussed [18].  
Loss of p53 function and p53 downregulation have been suggested to inhibit the apoptotic 
signal in resistant cells as well as to suppress caspase activity and dysregulate MAPK 
pathways [15]. Proteins of the B-cell lymphoma 2 (Bcl-2) family, which comprises 
pro-apoptotic and anti-apoptotic proteins, are also discussed to play a role in post-target 
resistance. Overexpression of anti-apoptotic Bcl-2 family proteins, like Bcl-2 or B-cell 
lymphoma-extra large (Bcl-xL), and deficiency of pro-apoptotic Bcl-2 family proteins, like 
Bcl-2–associated X protein (Bax), are not always but often associated with platinum 
resistance as well [18]. In breast cancer cells, Bcl-2 overexpression was associated with an 
increase in cellular GSH content and in resistance to cisplatin [22]. 
1.3.4 Off-target resistance 
Off-target resistance includes factors contributing to platinum resistance that are not directly 
linked to platinum-DNA adducts. Again, a variety of cellular processes have been reported 
and discussed in the literature and the following itemization is not necessarily exhaustive.  
Autophagy, an evolutionary conserved response to multiple stress conditions, as 
chemotherapy, was seen in tumor cells developing resistance [5]. It involves the lysosomal 
degradation of cytoplasmic organelles or cytosolic components and results in survival [23]. 
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Several heat shock proteins have been proposed to indirectly contribute to platinum resistance 
as well as altered mitochondria, altered signaling pathways, upregulation of chaperones and 
chromosomal changes [5]. 
Tab. 1-1 gives an overview of some factors contributing to pre-target, on-target, post-target 
and off-target-resistance. 
Tab. 1-1 Cellular processes and players involved in platinum resistance (modified from [5]). 
Pre-target On-target Post-target Off-target 
Reduced uptake 
 CTR1 
Increased efflux 
 ATP7A/ATP7B 
 MRP2 
Increased 
inactivation 
 GSH/γGCS/GST 
 Metallothioneins 
Increased repair of 
platinum-DNA adducts 
 Increased NER 
proficiency 
 HMG protein 
deficiency 
 Increased replicative 
bypass 
Increased tolerance to 
platinum-DNA adducts 
 MMR deficiency 
Increased apoptosis 
inhibitors 
Deficiency of 
apoptosis inductors 
Suppressed activity of 
caspases 
Dysregulation in 
MAPK pathways 
Reduced p53 function 
Altered cell signaling 
pathways 
Altered mitochondria 
Upregulation of 
chaperones 
Autophagy 
Heat shock proteins 
ATP7A, ATP7B: copper-transporting P-type adenosine triphosphatases A, B, CTR1: copper transporter 1; 
γGCS: γ-glutamylcysteine synthetase, GSH: glutathione, GST: glutathione S-transferase, HMG: high mobility 
group, MMR: mismatch repair, MRP2: Multidrug resistance-associated protein 2, NER: nucleotide excision 
repair. 
1.4 Glutathione 
Glutathione (γ-glutamylcysteinylglycine, GSH) is a tripeptide with an unusual gamma peptide 
linkage between the amine group of cysteine and the carboxyl group of the glutamate side-
chain (see Fig. 1-3). The unusual bond prevents GSH from hydrolyzation by most peptidases. 
GSH is the most abundant cellular thiol and can be found in most mammalian and prokaryotic 
cells [24]. 
 
Fig. 1-3 Chemical structure of glutathione (GSH). 
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GSH is synthesized in the cytosol of cells from its precursor amino acids by 
γ-glutamylcysteine synthetase (γGCS) and GSH synthetase (GS). The amount of GSH 
synthesized is controlled by the expression of γGCS and cysteine available. Most of the 
cellular GSH exists in the reduced state, only a small amount is oxidized or conjugated (see 
Fig. 1-4). The oxidized form, GSSG, is a disulfide which is derived from two GSH molecules. 
 
Fig. 1-4 Cellular GSH synthesis (modified from [25]).  
 ATP: adenosine triphosphate, L-Cys: cysteine, L-Glu: glutamine, L-Gly: glycine, GR: 
 GSSG reductase, GS: GSH synthetase, GS-R: GSH conjugates. 
GSH is degraded only in the extracellular space, mainly by the ectoenzyme γ-glutamyl 
transferase, which is located on the surface of cells. MRP1, MRP2 and organic anion-
transporting polypeptide 1 (OATP1) have been implied to transport GSH into the extracellular 
space for GSH regulation (see Fig. 1-5). Besides GSH, MRP1 and MRP2 also transport 
GSSG and GSH conjugates (GS-R). The affinity of MRP1 and MRP2 for transport of GSH is, 
however, lower compared to GSSG [26,27]. 
After synthesis, GSH is distributed in intracellular compartments such as mitochondria, 
endoplasmic reticulum (ER) and nucleus and excreted into the extracellular space. GSH 
probably enters the nucleus by passive diffusion through nuclear pores. Dicarboxylate and 
oxoglutarate carriers have been discussed to transport GSH in mitochondria; the mechanism 
GSHGSSG GS-R
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Na+
K+
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Na+
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of its transport into the ER is unclear [25]. For an overview of compartmentation and export 
of GSH see Fig. 1-5. 
 
Fig. 1-5 Distribution of GSH after its synthesis (modified after [25]). 
 ER: endoplasmic reticulum, GS-R: GSH conjugates, MRP1/2: Multidrug resistance-
 associated protein 1/2, OATP1: organic anion-transporting polypeptide 1. 
GSH is involved in many cellular processes of defense and metabolism, but above all, it acts 
as an antioxidant. The ratio of GSH to its oxidized form, GSSG, plays an important role in 
maintaining the cellular thiol-redox status. Changes in GSH/GSSG ratio have been associated 
with cell proliferation, differentiation and apoptosis. GSSG reductase (GR), a nicotinamide 
adenine dinucleotide phosphate (NADPH)-dependent enzyme, is responsible for keeping 
GSH in the reduced state [25].  
Formation of GSH S-conjugates and GSH complexes has been described for endogenous and 
exogenous compounds like drugs or toxins, either facilitating their cellular efflux or 
detoxification. Formation of conjugates can be either enzymatical and catalyzed by GSH-
S-transferases (GST) or non-enzymatical [24].  
GSH
GSSG
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Additionally, diverse proteins have been described to be reversibly glutathionylated, among 
them transcription factors, signaling proteins and enzymes with active site thiols. Protein 
S-glutathionylation is increasingly recognized as cell signaling and regulatory mechanism as 
many apoptotic/survival signaling pathways have been shown to be regulated by reversible 
S-glutathionylation [25,28].  
1.4.1 Glutathione in platinum resistance 
GSH is a topic of interest in platinum resistance. Increased cellular GSH content and elevated 
activity of γGCS, the rate-limiting enzyme in GSH synthesis, have been associated with 
resistance to platinum complexes repeatedly [25,29,30]. Additionally, treatment of cancer 
cells with buthionine sulfoximine (BSO), a GSH-depleting substance which lowers GSH 
synthesis by inhibiting γGCS, resulted in increased sensitivity to platinum drugs 
in vitro [29,31,32]. These findings, however, are controversial as others did not find increased 
platinum toxicity when treating cells with BSO [33]. Up to now, it is not clear whether 
elevated GSH content and γGCS are causally responsible for platinum resistance or whether 
they are an unspecific reaction to reactive oxygen species (ROS) induced by platinum 
complexes [29]. 
It has been postulated by many authors that inside the cell the reactive aqua species of the 
platinum complexes form platinum-GSH adducts [5,6,34,35]. Ishikawa and Ali-Osman 
reported the isolation of a 1:2 cisplatin-GSH adduct from L1210 murine leukemia cells and 
that about 60% of cellular cisplatin reacted with GSH [35]. The kinetics of the reaction of 
excess GSH with platinum complexes has been investigated in experiments in buffer solutions 
by others, showing a relatively slow rate of adduct formation for carboplatin-GSH 
adducts [36]. In this setting, reaction of oxaliplatin with GSH starts quickly but stops when 
oxaliplatin is depleted and monofunctional adducts are formed. The reaction of cisplatin with 
GSH starts almost as fast but continues even when all cisplatin is bound to GSH suggesting 
formation of bi- or multifunctional adducts. However, information on platinum-GSH adducts 
is insufficient with only two research papers describing the isolation of a platinum-GSH 
adduct from in vitro experiments with cell models [35,37]. After incubation of cell lysate 
produced from cisplatin-resistant ovarian cancer cells, mainly macromolecular and no 
cisplatin-GSH adducts were identified by others [38].  
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Besides resistance to platinum complexes, elevated GSH content has been associated with 
increased sensitivity. After transfection of small cell lung cancer derived cells with a γGCS 
subunit, an increased GSH content was found. In those cells formation of copper-GSH 
complexes and a decrease of available copper were observed. As a consequence an 
upregulation of copper transporter CTR1 was observed, contributing to augmented cisplatin 
toxicity by increased cisplatin uptake [29]. 
For completeness, the potential role of platinum-GSH adducts as drug reservoirs for DNA 
platination needs to be mentioned. Reedijk postulates that platinum-sulfur adducts, such as 
platinum-GSH adducts or platinum-protein adducts, may serve as a drug reservoir. Platinum 
could be released from sulfur and after that react with DNA or a direct nucleophilic 
displacement from sulfur by guanine-N might occur. The transfer, however, seems to be 
limited to platinum-thioether type adducts and transfer to N7 of guanines [39]. 
Bearing in mind also the regulation of signaling pathways by S-glutathionylation the 
mechanism of GSH-mediated platinum resistance is complex and is likely to be different in 
distinct cells and diverse mechanisms may take place simultaneously.  
Glutathione S-transferases 
Glutathione S-transferases (GST) are a group of multiple isoenzymes (named with Greek 
letters: α, μ, π, ω, θ, ζ). In general, GST catalyze a variety of reactions and accept endogenous 
and xenobiotic substrates. Enzymes differ widely in their amino acid sequence and different 
isoenzymes and polymorphic variations go along with diverse properties [40]. GST belong to 
the phase II detoxification enzymes. By catalyzing the reaction of GSH with electrophilic 
substances GST protect cellular proteins. They have been discussed to contribute to drug 
resistance by increasing their detoxification and hence inactivation of drugs. However, the 
relevance of GST in platinum resistance in terms of detoxification is probably low and their 
function in kinase-mediated pathways more important [41]. The GST subfamily GSTπ, 
encoded by the GSTP1 gene, is likely to contribute to resistance by controlling stress 
response, cellular proliferation and apoptosis by interaction with c-Jun N-terminal kinase 
(JNK). JNK is sequestered by GSTπ by formation of a JNK:GSTπ complex. Under condition 
of oxidative stress this complex dissociates and JNK regains functional capacity and can 
contribute to the induction of a stress cascade and potentially apoptosis. In this context GSTπ 
is understood to contribute to (platinum) drug resistance by interfering with drug-induced 
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apoptotic signaling. A polymorphism in GSTπ, however, was also associated with an 
improved response to platinum chemotherapy [40]. In clinical studies GSTπ expression 
inversely correlated with clinical outcome in patients with e.g. head and neck cancers or 
ovarian cancer treated with cisplatin [15,40,42] and polymorphisms leading to alterations in 
GSTπ protein primary structure were favorable for survival in patients with metastatic 
colorectal cancer treated with fluorouracil and oxaliplatin [43]. 
1.4.2 Glutathione as cytoprotective agent 
As described above, GSH is discussed to be involved in resistance of tumor cells to platinum 
complexes. But GSH has also been administered to patients prior to platinum complexes to 
reduce toxicity. In patients treated with cisplatin or oxaliplatin, renal and neurological toxicity 
were ameliorated after intravenous administration of GSH without loss of antitumor effects 
although total GSH and cysteine in plasma increased significantly [44-47]. In animal 
experiments the protective GSH dose did not appear to influence the antitumor effects 
either [45]. In patients treated with fluorouracil and oxaliplatin a significant reduction of 
neurotoxicity was seen when patients received GSH before administration of chemotherapy. 
The formation of platinum-DNA adducts in leukocytes was not altered in these patients 
suggesting no GSH influence on platinum-DNA adduct formation in tumor cells [48].  
1.5 Multidrug resistance-associated proteins 
Multidrug resistance-associated proteins (MRP), as the name suggests, are established to be 
involved in resistance to diverse drugs and in the phenomenon of multidrug resistance (MDR) 
in cancer. MRP belong to the superfamily of ATP-binding cassette (ABC) transporter as they 
utilize energy from adenosine triphosphate (ATP) hydrolysis to transport substrates across 
membranes. ABC transporters are composed of two nucleotide-binding domains (NBD) and 
different numbers of membrane-spanning domains (MSD). Seven subfamilies of ABC 
transporters have been described so far (ATP-binding cassette sub-family A to G: ABCA to 
ABCG). Beside MRP, prominent members of ABC transporters involved in MDR are 
P-glycoprotein (P-gp) (ABCB1, also called MDR1) and breast cancer resistance protein 
(BCRP) (ABCG2). Subfamily ABCC is the biggest family comprising transporters which 
differ in structure, substrate specificity and cellular location, among them MRP [49]. MRP are 
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expressed in tissues that require protection from endogenous substances including liver, 
intestines and kidney. But beside transport of toxins they also transport endogenous 
substances [50].  
In the context of platinum resistance MRP1 (ABCC1) and MRP2 (ABCC2) appear to be of 
importance [51,52]. These transporters, however, differ with regard to the tissues they are 
expressed in. MRP2 is also referred to as ‘canalicular multispecific organic anion 
transporter 1‘ (cMOAT), since it is expressed in the canalicular (apical) part of hepatocytes 
and transports small organic anions. Localization and substrates of MRP1 and MRP2 are 
shown in Tab. 1-2. It has to be considered that controversial information about the transport 
of cisplatin by MRP1 is found in literature. 
Tab. 1-2 Localization and substrates of MRP1 and MRP2, nonexhaustive  
 enumeration [26,49,50,52,53]. 
Transporter Tissues Substrates 
  physiological drugs (assumed) 
MRP1 ‘Ubiquous’, highest 
levels in lung, testis, 
kidney, skeletal and 
cardiac muscles, 
placenta and 
macrophages 
Leukotriene C4, 
leukotriene D4, folate, 
Estrone 3-sulfate, glucuronic 
acid conjugates of estradiol 
and bilirubin,  
GSH conjugate of 
prostaglandin A2 
Doxorubicin, daunorubicin, 
etoposide, rhodamine, 
ciclosporin, GSH adducts 
of melphalan and 
chlorambucil, cisplatin 
MRP2 Liver, kidney, 
intestine, gall 
bladder, placenta, 
peripheral nerves, 
placental trophoblast 
Leukotriene C4, glucuronic 
acid conjugates of estradiol 
and bilirubin, sulfate 
conjugate of estradiol 
Doxorubicin, etoposide, 
methotrexate, 
mitoxantrone, vinblastine, 
sulfinpyrazone, ampicillin, 
pravastatin, cisplatin 
Resembling each other in topology, MRP1 and MRP2 are identical in only 49% of amino 
acids and as mentioned above differ with regard to expression pattern (see Fig. 1-6 for 
topology model of MRP1 and MRP2). Despite their difference in amino acids, they show 
similar substrate specificity. The kinetic properties of substrate transport of MRP1 and MRP2, 
however, are different. For instance, MRP2 shows higher affinity for mono- and 
bisglucuronosyl bilirubin than MRP1 whereas MRP1 has higher affinity for 
leukotriene C4 [26,49]. In case of MRP2 two distinct binding sites were discussed; one 
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binding site seems responsible for drug transport, the other one for regulation of 
transport [49,52]. 
 
Fig. 1-6 Topology model of MRP1 and MRP2 (top: extracellular space, bottom: intracellular 
 space). Controversial topology models of MRP2 consisting of only four transmembrane 
 helices in MSD2 exist [49].  
 NBD: nucleotide-binding domain, MSD: membrane-spanning domain, Y: glycosylation. 
Active substances such as verapamil and ciclosporin inhibit MRP1- and MRP2-mediated 
efflux, but also the efflux via P-gp. Only few specific modulators for MRP have been 
described to date, among them 4-aminobenzoic acid derivatives. In case of Gü83 (see  
Fig. 1-7) inhibition of MRP1- (IC50 = 1.21 µM) and of MRP2-mediated efflux 
(IC50 = 21.5 µM) but not of P-gp-mediated efflux has been reported by Leyers et al. using cell 
lines stably expressing the particular transporter [54]. 
 
Fig. 1-7 Chemical structure of the MRP modulator Gü83 (4-[(5,6,7,8-tetrahydro-4-oxo-4H-[1] 
 benzo-thieno[2,3-d][1,3]thiazin-2-yl)amino]benzoic acid). 
NH2
COOH
NBD1
NBD2
MSD0 MSD1 MSD2
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1.5.1 MRP in platinum resistance 
Experiments in Madin-Darby canine kidney cells (MDCKII) stably expressing either MRP1 
or MRP2 have indicated that cisplatin might be transported by both MRP1 and MRP2 [53]. 
The results of experiments with human cancer cells, however, predominately suggest an 
association of MRP2 overexpression but not of MRP1 overexpression with platinum 
resistance [55].  
MRP1 is reported to be highly expressed in leukemias, esophageal carcinomas and non-small 
cell lung cancer [52]. Most cancer cell experiments did not suggest a direct association of 
MRP1 expression with resistance to cisplatin or other platinum complexes [9]. Bracht et al. 
found no correlation between MRP1 expression and sensitivity to cisplatin, carboplatin or 
oxaliplatin in 14 human cancer cell lines [56]. In a panel of 30 unselected lung cancer cell 
lines, however, a correlation of MRP1 expression and cisplatin sensitivity was observed [57]. 
Recently published studies suggest an association of nuclear MRP1 with resistance to 
cisplatin [58].  
MRP2 is expressed in some solid tumors originating from the kidney, colon, breast, lung and 
ovaries and in leukemic blasts [52] and there is evidence from in vitro experiments that MRP2 
is involved in platinum resistance. In human pancreatic cancer cells the MRP2 but not the 
MRP1 expression level was associated with cisplatin resistance [59]. The level of DNA 
platination after incubation with cisplatin correlated inversely with the level of MRP2 
expression in melanoma cells also suggesting an impact of MRP2 on cisplatin toxicity [60]. 
Investigating diverse human cancer cell lines overexpressing MRP2 the reversal of resistance 
to cisplatin was achieved by MRP2 knock out by anti-MRP2 hammer-head ribozymes [61]. In 
a panel of esophageal squamous cell carcinoma (ESCC) cell lines high MRP2 mRNA 
expression correlated with resistance to cisplatin, which could be reduced by inhibition of 
MRP2 expression by small-interfering RNA (siRNA) [62]. In a human ovarian cancer cell 
line and its cisplatin-resistant variant an increase in sensitivity to cisplatin was achieved by 
short hairpin RNA (shRNA) decreasing MRP2 expression [63]. An increase of MRP2 protein 
expression could be induced by cisplatin in a cisplatin-resistant ovarian carcinoma cell 
line [64].  
In contrast, in colorectal adenocarcinoma cells an increased expression of MRP2 induced by 
fluorouracil resulted in sensitization to oxaliplatin. Authors suggested that an increased GSH 
efflux via MRP2 could lead to the increased sensitivity [65]. There are more data suggesting 
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that the contribution of MRP2 could strongly depend on cell-type. In cervical cancer cells a 
20-fold lower MRP2 expression was found in cells resistant to cisplatin compared to the 
sensitive cells [66]. 
Clinical relevance of MRP-mediated efflux in platinum resistance 
The assumption that rather MRP2 than MRP1 is relevant for platinum resistance is also 
confirmed when considering clinical data. In tumor samples of colorectal cancer patients an 
upregulation of MRP2 in cancerous regions compared with noncancerous regions was 
described and hypothesized to be associated with resistance to cisplatin [67]. In patients 
suffering from hepatocellular carcinoma (HCC) a negative correlation of MRP2 expression in 
resected specimens and tumor necrosis after cisplatin-based chemotherapy was found, 
suggesting that expression of MRP2 is associated with the efficacy of the chemotherapy 
regimen [68]. In a similar study with resected esophageal squamous cell carcinoma (ESCC) 
specimens the MRP2-positive patients showed poorer prognosis than MRP2-negative patients 
with regard to 5-year survival rate (25.6% vs. 55.7%) [62]. In tumor samples from patients 
with small cell lung cancer (SCLC), MRP2 expression but not MRP1 expression was 
associated with a worse response to cisplatin-containing chemotherapy [69]. In samples from 
patients suffering from ovarian cancer, MRP2 was found in the nuclear membrane. Weak 
expression of MRP2 in the nuclear membrane was associated with longer progression-free 
and overall survival. Interestingly, the correlation of MRP2 expression and survival was only 
found for MRP2 in the nuclear membrane and not for MRP2 in the cytoplasmic 
membrane [64]. 
1.6 Interaction between glutathione and MRP in platinum resistance 
In the previous chapters the relevance of GSH (see chapter 1.4.1) and MRP-mediated efflux 
(see chapter 1.5.1) for platinum resistance were discussed separately but their interaction 
needs to be considered as well. MRP1 and MRP2 transport various endo- and exogenous 
substances and besides GSH and oxidized GSH (GSSG), GSH conjugates are 
substrates [26,27]. As formation of GSH conjugates was reported for platinum complexes and 
MRP have been associated with platinum resistance, an MRP mediated efflux of platinum-
GSH adducts suggests itself. 
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However, the interaction of GSH and MRP in terms of excretion of endo- and exogenous 
substances is diverse and goes beyond the transport of GSH conjugates. GSH can be 
co-transported with substances or it can stimulate their transport without being transported 
itself. But also MRP1- and MRP2-mediated GSH transport has been reported to be stimulated 
by xenobiotics, even by substances that are not substrates [26,49,55]. GSH might even be 
required as a co-factor for the transport of GSH conjugates [50]. The possible scenarios of 
interaction of GSH, MRP and endo- or exogenous substances are summarized in Fig. 1-8. 
 
Fig. 1-8 Export of GSH and endogenous substances through MRP1 and MRP2. A transport of 
 GSH conjugate, B transport stimulated by GSH, C co-transport, D substance stimulates 
 GSH efflux but is not substrate (adapted from [55]). 
 X: endo- or exogenous substance (e.g. platinum complex), GS-X: GSH conjugate of X. 
According to literature, in case of platinum complexes MRP-mediated efflux of GSH adducts 
is most probable and associated with platinum resistance [5,6,34,35]. Available data are, 
however, conflicting as results of in vitro experiments have also suggested that GSH does not 
play a role in cisplatin transport [53]. 
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2 AIM AND OBJECTIVES 
Platinum complexes are used in a variety of cancer chemotherapy regimens. However, the 
success of therapy is often limited as many tumor cells are intrinsically resistant or acquire 
resistance towards platinum complexes. By now it is known that various factors contribute to 
resistance. One of them is glutathione (GSH) which has been associated with platinum 
resistance for a long time. The mechanisms involving GSH were addressed in this project as 
they have not been fully elucidated yet. As the efflux of platinum complexes or platinum-
GSH adducts via MRP2 is often discussed with regard to resistance, this efflux transporter has 
been considered in this research project as well. 
Within the scope of this project the relevance of glutathione and MRP-mediated efflux for 
platinum resistance should be revealed in human cancer cell lines and their platinum-resistant 
variants. For this purpose, the following objectives were defined: 
 Determination of the cellular GSH content. 
 Determination of changes in cellular GSH content after exposure of the cells to 
platinum complexes. 
 Determination of sensitivity of the cells towards platinum complexes after GSH 
depletion. 
 Identification of changes in cellular platinum accumulation after GSH depletion. 
 Identification of possible cisplatin- and oxaliplatin-GSH adducts. 
 Determination of expression and localization of MRP2. 
 Determination of alterations in cellular platinum accumulation and DNA platination 
using MRP modulators. 
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3 MATERIALS AND METHODS 
3.1 Chemicals and reagents 
Acrylamide 30% [m/V] AppliChem GmbH, Darmstadt 
Alexa Fluor
®
 488 goat anti-chicken IgG Invitrogen, Karlsruhe 
antibody 
Anti-mouse IgG horseradish peroxidase- R&D Systems GmbH, Wiesbaden-  
conjugated antibody Nordenstadt 
Anti-goat IgG horseradish peroxidase- R&D Systems GmbH, Wiesbaden-  
conjugated antibody  Nordenstadt 
Argon 4.6 Air Product, Hattingen 
BCA protein assay kit (Novagen
®
): Merck KGaA, Darmstadt 
 Albumin standard ampoules (2 mg/mL 
 bovine serum albumin) 
 Reagent A (bicinchoninic acid) 
 Reagent B (4% cupric sulfate) 
β-Actin (C4) antibody (mouse polyclonal IgG) Santa Cruz Biotechnology, Inc., 
Heidelberg 
Ammonium persulfate (APS) AppliChem GmbH, Darmstadt 
Boric acid  Fluka Chemie, Neu-Ulm 
Bovine serum albumin (BSA) Sigma-Aldrich, Steinheim 
Bromophenol blue AppliChem GmbH, Darmstadt 
Buthionine sulfoximine (BSO) Fluka Chemie, Neu-Ulm 
Acetomethoxy derivative of Calcein Sigma-Aldrich, Steinheim 
(calcein AM) 
CASYton, isotonic diluting solution Schärfe System, Reutlingen 
Cisplatin Sigma-Aldrich, Steinheim 
Cobalt(II) sulfate heptahydrate Sigma-Aldrich, Steinheim 
2-(4-Amidinophenyl)-1H-indole-6- Sigma-Aldrich, Steinheim 
carboxamidine-dihydrochloride  
(DAPI) 
Dimethylsulfoxide (DMSO) Riedel-de Haën, Seelze 
3-(4,5-Dimethylthiazol-2-yl)-2,5-  AppliChem, Darmstadt 
diphenyltetrazolium bromide (MTT) 
Disodium hydrogen phosphate dihydrate Merck KGaA, Darmstadt 
MATERIALS AND METHODS 
21 
 
Dithiothreitol (DTT) Applichem, Darmstadt 
Elektrophoresis buffer, 10 x [25 mM Tris base, Bio-Rad Laboratories GmbH, München 
192 mM glycin, 0.1% sodium dodecyl sulfate] 
Ethanol 96-100 % [V/V] Merck KGaA, Darmstadt 
Ethylenediaminetetraacetic acid (EDTA)-  Sigma-Aldrich, Steinheim 
disodium salt dihydrate 
Fetal calf serum (FCS)  Sigma-Aldrich, Steinheim 
Fluoromount™ aqueous mounting medium Sigma-Aldrich, Steinheim 
Formaldehyde 37 % [m/V] Riedel de Haën AG, Seelze 
Glucose monohydrate Sigma-Aldrich, Steinheim 
Glutathion (GSH) Sigma-Aldrich, Steinheim 
Glycerol 100% [V/V] Applichem GmbH, Darmstadt 
Glycine Grüssing GmbH, Filsum 
4-(2-hydroxyethyl)-1-piperazineethane- Applichem GmbH, Darmstadt 
sulfonic acid (HEPES)  
Hydrochloric acid [0.1 M and 1.0 M]  Riedel de Haën AG, Seelze 
Hydrochloric acid 37% [m/V] Merck KGaA, Darmstadt 
Isopropanol 100% [V/V] Merck KGaA, Darmstadt 
Leupeptin hemisulfate Sigma-Aldrich GmbH, Steinheim 
L-Glutamin solution [200 mM] Sigma-Aldrich, Steinheim 
Methanol Merck KGaA, Darmstadt 
Milk powder Carl Roth GmbH & Co. KG, Karlsruhe 
Monosodium phosphate Fluka Chemie, Neu-Ulm 
MRP2 (H-17) antibody (goat polyclonal IgG) Santa Cruz Biotechnology, Inc., 
Heidelberg 
Naphthalene-2,3-dicarboxaldehyde (NDA) Sigma-Aldrich, Steinheim 
Nitric acid 65% [V/V], suprapur Merck KGaA, Darmstadt 
Oxaliplatin Sigma-Aldrich, Steinheim 
Penicillin streptomycin solution  Sigma-Aldrich, Steinheim 
[10,000 I.E./mL, 10 mg/mL] 
Pepstatin A Sigma-Aldrich, Steinheim 
Perchloric acid 70% Sigma-Aldrich, Steinheim 
Pierce ECL Western Blotting Substrate  Thermo Fisher Scientific Inc., 
(luminol/enhancer, peroxide buffer) Rockford, USA 
Potassium chloride  Merck KGaA, Darmstadt 
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Potassium dihydrogen phosphate Fluka Chemie GmbH, Neu-Ulm 
QIAmp DNA Mini Kit:  Qiagen, Hilden 
 Buffer AE (elution buffer) 
 Buffer AL (lysis buffer) 
 Buffer AW 1 (wash buffer) 
 Buffer AW 2 (wash buffer) 
RPMI-1640 medium Sigma-Aldrich, Steinheim 
Ribonuclease A (RNAse) Sigma-Aldrich, Steinheim 
Roti
®
-Mark (protein marker), prestained Carl Roth GmbH & Co. KG, Karlsruhe 
Sodium azide Fluka Chemie, Neu-Ulm 
Sodium bicarbonate Fluka Chemie, Neu-Ulm 
Sodium chloride Fluka Chemie, Neu-Ulm 
Sodium dihydrogen phosphate monohydrate Sigma-Aldrich, Steinheim 
Sodium dodecyl sulfate (SDS) Applichem GmbH, Darmstadt 
Sodium hydroxide [0.1 M and 1.0 M] Riedel de Haën AG, Seelze 
Sodium orthovanadate Applichem GmbH, Darmstadt 
Tetramethylethylenediamine (TEMED) Applichem GmbH, Darmstadt 
Tergitol solution Sigma-Aldrich, Steinheim 
Tris(hydroxymethyl)aminomethane  Applichem GmbH, Darmstadt 
(Tris base) 
Triton
®
 X-100 Sigma-Aldrich, Steinheim 
Trypsin-EDTA solution [0.5 g porcine Sigma-Aldrich, Steinheim 
trypsin and 0.2 g EDTA in 100 ml] 
Tween
®
-20 Applichem GmbH, Darmstadt 
Ultrapure water Obtained by Purlab Plus™ system, Elga 
 Labwater, Celle 
3.2 Buffers and solutions 
Phosphate buffered saline (PBS) 
 Sodium chloride  8.0 g 
 Potassium chloride  0.2 g 
 Disodium hydrogen phosphate dihydrate 1.44 g 
 Potassium dihydrogen phosphate 0.24 g 
 Ultrapure water ad 1000.0 mL 
 pH adjusted to 7.4 using sodium hydroxide or hydrochloric acid 
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Cisplatin stock solution [5 mM] 
 Cisplatin 1.5 mg 
 Sodium chloride solution 0.9% 1.0 mL 
Oxaliplatin stock solution [10 mM] 
 Oxaliplatin 3.97 mg 
 Ultrapure water 1.0 mL 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution [5 mg/mL] 
 MTT 10 mg 
 PBS 2.0 mL 
Ribonuclease A (RNase) solution [100 mg/mL] 
 RNase 10 mg 
 Buffer AL (from QIAmp DNA Mini Kit) 100.0 µL 
3.2.1 Glutathione quantification 
Borate buffer pH 9.2 [100 mM] 
 Boric acid 618.4 mg 
 Ultrapure water ad 100.0 mL 
 pH adjusted to 9.2 using sodium hydroxide 
Dithiothreitol (DTT) solution [100 mM] 
 DTT 30.9 mg 
 Borate buffer 9.2 2.0 mL 
Glutathione (GSH) stock solution [10 mM] 
 GSH 37.2 mg 
 Hydrochloric acid [0.1 M] / EDTA [1 mM] (see below) ad 100.0 mL 
HCl 0.1 M / EDTA [1 mM] 
 Na2EDTA ∙ 2 H2O 30.7 mg 
 HCl 0.1 M ad 10.0 mL 
GSH working solution 1 [100 µM] 
 GSH stock solution 100 µL 
 Perchloric acid 3.3% (see below) ad 10.0 mL 
GSH working solution 2 [10 µM] 
 GSH working solution 1 1000 µL 
 Perchloric acid 3.3% (see below) ad 10.0 mL 
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Perchloric acid (HClO4) 3.3% 
 Perchloric acid 70% 4.7 g 
 Ultrapure water ad 100.0 mL 
Naphthalene-2,3-dicarboxaldehyde (NDA) solution [5 mM] 
 NDA 9.2 mg 
 DMSO ad 10.0 mL 
3.2.2 SDS page and protein immunoblotting 
Cell lysis 
Lysis buffer 
Tergitol solution 10.0 mL 
Tris base 2.423 g 
Sodium chloride 8.006 g 
Glycerol 100.0 mL 
EDTA 0.584 g 
Activated sodium orthovanadate [10 mM]* 100.0 mL 
Ultrapure water ad 1000.0 mL 
Leupeptin solution [5 mg/mL in ultrapure water]** 2 µL 
Pepstatin A solution [2 mg/mL in DMSO]** 5 µL 
* Solution of sodium orthovanadate [10 mM] in ultrapure water, pH adjusted to 10 and 
 solution boiled yielding a clear solution. After cooling down readjusted pH to 10. 
** Leupeptin and Pepstatin A solution were added shortly before usage. 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Ammonium persulfate (APS) solution [10%] 
 APS 100 mg 
 Ultrapure water as 1000.0 µL 
Dithiothreitol (DTT) solution [3.2 M] 
 DTT 49.4 mg 
 Ultrapure water ad 1000.0 µL 
Loading buffer 
 Stacking gel buffer 1.75 mL 
 Glycerol 1.5 mL 
 Sodium dodecyl sulfate solution (see below) 5 mL 
 Bromophenol blue solution* 1.25 mL 
 * Saturated bromphenol blue solution in ultrapure water containing 0.1% ethanol. 
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Sodium dodecyl sulfate (SDS) solution [10%] 
 SDS 1.0 g 
 Ultrapure water ad 10.0 mL 
Stacking gel 
 Acrylamide 30% 833 µL 
 Stacking gel buffer (see below) 625 µL 
 Ultrapure water 3445 µL 
 SDS 10% 50 µL 
 TEMED* 5 µL 
 APS 10%* 20.8 µL 
 * Added last for initiation of polymerization. 
Stacking gel buffer (pH 6.8) 
 Tris base 12.11g 
 Ultrapure water ad 100.0 mL 
 pH adjusted to 6.8 
Separating gel 
 Acrylamide 30% 5000 µL 
 Separating gel buffer (see below) 5625 µL 
 Ultrapure water 4093 µL 
 SDS 10% 150 µL 
 TEMED* 27 µL 
 APS 10%* 105 µL 
 * Added last for initiation of polymerization. 
Separating gel buffer (pH 8.8) 
 Tris base 12.11g 
 Ultrapure water ad 100.0 mL 
 pH adjusted to 8.8 using hydrochloric acid 
Western Blot 
Tris-buffered saline (TBS) 
 Sodium chloride 4 g 
 Tris base 0.6 g 
 Ultrapure water ad 500.0 mL 
 pH adjusted to 7.3 using hydrochloric acid 
Tris-buffered saline with Tween
®
-20 (TBS-T) solution 
 Tween®-20 1.6 mL 
 TBS ad 800.0 mL 
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Blocking solution 
 Milk powder 5 g 
 TBS-T solution ad 100.0 mL 
Transfer buffer 
 Glycine 14.4 g 
 Tris base 3 g 
 Ultrapure water ad 800.0 mL 
 pH adjusted to 8.2 to 8.4 using hydrochloric acid 
Antibody solutions for visualization of proteins 
Primary antibody MRP2 solution [1:500] 
 Sodium azide 10 mg 
 BSA 500 mg 
 MRP2 (H-17) antibody (goat polyclonal IgG) 20 µL 
 TBS-T solution 10.0 mL 
Primary antibody β-Actin solution [1:4000] 
 Sodium azide 10 mg 
 BSA 500 mg 
 β-Actin (C4) antibody (mouse polyclonal IgG) 2.5 µL 
 TBS-T solution 10.0 mL 
Secondary anti-goat antibody solution [1:1000] 
 Milk powder 0.5 g 
 Anti-goat IgG horseradish peroxidase-conjugated antibody 10 µL 
 TBS-T solution 10.0 mL 
Secondary anti-mouse antibody solution [1:1000] 
 Milk powder 0.5 g 
 Anti-mouse IgG horseradish peroxidase-conjugated antibody 10 µL 
 TBS-T solution 10.0 mL 
3.2.3 Calcein assay 
Acetomethoxy derivative of calcein (calcein AM) stock solution [1 mM] 
 Calcein AM  2 mg 
 Ultrapure water 2 mL 
Calcein AM working solution [0.31 µM] 
 Calcein AM stock solution  5 µL 
 KHP (see below) ad 4.0 mL 
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Krebs HEPES buffer (KHP) 
 Sodium chloride  3450 g 
 Potassium chloride  175 µg 
 Potassium dihydrogen phosphate 82 µg 
 Sodium bicarbonate 18 µg 
 Glucose monohydrate 1158 µg 
 HEPES 1192 µg 
 Ultrapure water ad 500.0 mL 
 pH adjusted to 7.4  
Cobalt(II) sulfate stock solution [10 mM] 
 Cobalt(II) sulfate heptahydrate 28.1 mg 
 Ultrapure water 10 mL 
Cobalt(II) sulfate working solution [10 µM] 
 Cobalt(II) sulfate stock solution 10 µL 
 Ultrapure water ad 10 mL 
3.2.4 Immunocytochemistry 
Bovine serum albumin (BSA) solution 1% 
 BSA  150 mg 
 PBS 15 mL 
MRP2 antibody solution [1:20] 
 MRP2 (H-17) antibody (goat polyclonal IgG) 2.5 µL 
 1% BSA solution 47.5 µL 
Alexa 488 antibody solution [1:100] 
 Alexa Fluor® 488 goat anti-chicken IgG antibody 6 µL 
 1% BSA solution 594 µL 
DAPI stock solution [1 mg/mL] 
 DAPI 1 mg 
 Methanol 1000 µL 
DAPI working solution [5 µg/mL] 
 DAPI stock solution 5 µL 
 Ultrapure water ad 1000 µL 
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3.3 Equipment 
Axiovert
®
 25 inverted microscope Carl Zeiss AG, Oberkochen 
Beckman Microfuge
®
 Lite Beckman-Coulter, Fullerton, USA 
Casy
®
1 cell counter, Modell TT Schärfe System, Reutlingen 
Centrifuge Universal 32R Hettich GmbH & Co. KG, Tuttlingen 
Centrifuge Mikro 200R Hettich GmbH & Co. KG, Tuttlingen 
ESI-Q-qTOF QSTAR XL Applied Biosystems, Darmstadt 
Fluoroskan Ascent
®
 microplate reader Thermo Fisher Scientific, Langenselbold 
FLUOstar
™
 OPTIMA microplate reader BMG LABTECH GmbH, Ortenberg 
ICP-MS Varian 820  Varian (Agilent Technologies), Darmstadt 
Incubator Thermo Thermo Electron GmbH, Dreieich 
InoLab
®
 pH level 2 pH Meter WTW GmbH, Weilheim 
Kern 770 analytical balance Kern & Sohn GmbH, Balingen-Frommern 
Kern EW analytical balance Kern & Sohn GmbH, Balingen-Frommern 
Laminar air flow work bench Heraeus Holding GmbH, Hanau 
MT Classic AB135-S analytical balance  Mettler-Toledo GmbH, Giessen 
LUMIstar
™
 Optima microplate reader BMG Labtech GmbH, Offenburg 
Multiskan Ascent
®
 microplate reader Thermo Fisher Scientific, Langenselbold 
Multiskan EX
®
 microplate reader Thermo Electron GmbH, Dreieich 
Nikon A1 Eclipse Ti confocal microscope Nikon, Kingston, UK 
Purelab Plus
™
 system ELGA LabWater, Celle 
Shaker KS 15 control Edmund Bühler GmbH, Hechingen 
Ultrasonic bath Sonorex
®
 Super RK 103 H Bandelin, Berlin 
UNIVAPO 100H Vacuum Concentrator  UniEquip GmbH, Planegg 
Centrifuge 
Western blot analysis 
VersaDoc™ Imaging System 5000 Bio-Rad Laboratories GmbH, München 
Blotting equipment Mini-Protean
®
 II Bio-Rad Laboratories GmbH, München 
Elektrophoresis equipment Mini-Protean
®
 II Bio-Rad Laboratories GmbH, München 
Thermo EC Dual Mode Electrophoresis  E-C Apparatus Corporation, 
Power Supply Milford, USA 
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Atomic absorption spectrometry 
Graphite tube atomizer GTA 100 Varian (Agilent Technologies), Darmstadt 
Sample dispenser PSD 100 Varian (Agilent Technologies), Darmstadt 
Spectrometer SpectrAA
®
 Zeeman 220 Varian (Agilent Technologies), Darmstadt 
3.3.1 Consumables 
Blotting paper (cellulose), 7 x 10 cm Sigma-Aldrich GmbH, Steinheim 
Casy
®
 tubes Schärfe System, Reutlingen 
Cell culture flasks 25, 75, 175 cm
2
 Sarstedt AG & Co., Nümbrecht 
Cell scraper Sarstedt AG & Co., Nümbrecht 
Conical centrifuge tubes 15, 50 mL Sarstedt AG & Co., Nümbrecht 
Cover slips (round, square) Carl Roth GmbH & Co., Karlsruhe 
Cryovials Sarstedt AG & Co., Nümbrecht 
Disposable syringe (10 mL) B. Braun Melsungen AG, Melsungen 
Glass Pipettes Labomedic GmbH, Bonn 
Graphite tubes Varian (Agilent Technologies), Darmstadt 
Microscope slides Carl Roth GmbH & Co., Karlsruhe 
Pasteur pipettes Brand GmbH & Co., Wertheim 
Petri dishes Greiner Labortechnik, Frickenhausen 
Pipette tips Brand GmbH & Co., Wertheim 
Platinum hollow cathode lamps Varian (Agilent Technologies), Darmstadt 
(UltrAA
®
 lamps) 
PVDF (Polyvinylidene fluoride) membrane Carl Roth GmbH & Co.KG, Karlsruhe 
QIAamp
®
 DNA Mini Kit Qiagen, Hilden 
Reaction tubes (0.5, 1.5, 2 mL) Greiner Labortechnik, Frickenhausen 
Sample vials (2 mL, conical) Varian (Agilent Technologies), Darmstadt 
Tissue culture plates, 96 wells Sarstedt AG & Co., Nümbrecht 
Tissue culture plates, 6 wells Sarstedt AG & Co., Nümbrecht 
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3.3.2 Software 
Accelrys Draw 4.0 Accelrys. Inc., San Diego, USA 
Analyst
®
 QS software Applied Biosystems, Foster City, USA 
Ascent Software (for Multiskan EX
®
) Thermo Electron Inc., Dreieich 
GraphPad Prism
®
, version 4.00 GraphPad Software, San Diego, USA 
Microsoft
®
 Excel 2007 Microsoft Corporation, Redmond, USA 
MVA
®
 2.0 NOVIA, Frankfurt am Main 
NIS-Elements software Nikon, Kingston, UK 
Quantity One
®
 - 4.6.1 Bio-Rad Laboratories GmbH, München 
SpectrAA
®
 220, Version 2.20 Varian, Darmstadt 
3.4 Cell culture 
3.4.1 Cell lines and cultivation 
In this project the human ileocecal colorectal adenocarcinoma cell line HCT-8 and the 
oxaliplatin-resistant variant HCT-8ox (kindly provided by Dr. M. Heim, University of Essen, 
Germany) as well as the ovarian carcinoma cell line A2780 and the cisplatin-resistant variant 
A2780cis (European Collection of Cell Cultures, United Kingdom) were used. The 
oxaliplatin-resistant variant of HCT-8, HCT-8ox, had been obtained after incubation with 
increasing concentrations of oxaliplatin in turns with incubation in drug-free medium [70]. 
The cisplatin-resistant variant of A2780, A2780cis, had been obtained after a similar 
procedure using cisplatin [71]. 
Cells were cultivated as monolayers in RPMI-1640
®
 medium supplemented with 10% fetal 
calf serum (FCS), 100 U/mL penicillin and 0.1 mg/mL streptomycin (37 °C, 5% CO2). For 
A2780 and A2780cis the medium was additionally supplemented with 0.6 mM L-glutamine. 
Cells were cultivated to a confluence of about 90% and then sub-cultivated or used for 
experiments. Backups of each cell line suspended in FCS containing 10% DMSO were stored 
in liquid nitrogen. After using cells over a period of 12 passages at most they were discarded 
and a new backup was thawed. Level of resistance of the resistant variants was monitored by 
the MTT-based cytotoxicity assay (see chapter 3.5). If a distinct number of cells was needed 
for an experiment, cells in a cell suspension were counted by electronic pulse area analysis 
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using a Casy
®
1 cell counter. Distribution of cell volume and cell aggregation was assessed at 
the same time. 
3.4.2 Mycoplasma test 
The genus mycoplasma comprises small prokaryotes (0.22 to 2 µm) without a cell wall, which 
can grow on cultivated mammalian cells and are not sensitive towards common antibiotics. 
Contamination with mycoplasma bacteria frequently occurs in cell culture and can bias 
research findings. Hence cells were regularly screened for mycoplasma infections using 
2-(4-Amidinophenyl)-1H-indole-6-carboxamidine-dihydrochloride (DAPI). DAPI binds 
cellular DNA and can be detected by fluorescence microscopy after exciting with ultraviolet 
light through a blue filter.  
Performing the assay, cells were seeded out on microscope slides in a petri dish. After three to 
four days the medium was removed, the slide washed with cold PBS and 80 µL of DAPI 
working solution as well as 2 mL methanol were added and left for 5 min. The slide was then 
washed with 2 mL methanol and cover slips were fixed on the slides using mounting medium. 
Cells were then analyzed using a Nikon Eclipse Ti fluorescence microscope. If a blue shade 
surrounding cells, accounting for stained mycoplasma DNA, had been seen, a mycoplasma 
infection was probable. These cells were discarded. 
3.5 Cytotoxicity assay 
Cytotoxic properties of compounds and in consequence the sensitivity of cells towards these 
compounds were assessed using the MTT assay [72]. The assay is based on the reduction of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), a yellow tetrazole, to a 
purple formazan (see Fig. 3-1). As the reduction is performed by mitochondrial 
dehydrogenases of living cells, the amount of purple formazan built is inversely proportional 
to the cytotoxicity of a compound.  
The assay was performed in 96-well plates. In each well a number of 3∙103 cells (HCT-8, 
HCT-8ox) or 10∙103 cells (A2780, A2780cis) was seeded out in 90 µL cell culture medium 
and allowed to attach overnight (37 °C, 5% CO2). The outer wells of the plate were not used 
for the experiment as evaporation might occur during the experiment. Therefore, those wells 
were filled with PBS only. On the next morning 10 µL of the solution of the compound 
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investigated was added to each well. Here, usually a control (ultrapure water or sodium 
chloride solution 0.9%) and nine increasing concentrations of the compound were used. Each 
concentration was tested in triplicate. 
 
Fig. 3-1 Reaction of yellow MTT to a purple formazan. 
The plates were incubated for 72 h (37 °C, 5% CO2). Subsequently, 20 µL of MTT in PBS 
(5 mg/mL) was added and the plates incubated for 1 h (37 °C, 5% CO2). The supernatant was 
then removed by carefully beating the plate upside down on tissue. The cells and the 
formazan crystals built were then lysed by addition of 100 µL of DMSO. The plates were 
shaken and the UV absorbance at 570 nm with background subtraction at 690 nm was 
measured using a Multiskan Ascent
®
 microtiter plate reader. The procedure described was 
adapted from [73] but slightly modified (cell and formazan lysis with DMSO instead of 1:1 
isopropanol and 1 M HCl as described by [72]). Dose-effect curves were calculated by 
non-linear regression using the software GraphPad Prism
®
 (settings: no comparison, 
constraint: ‘BOTTOM must be greater than 0.0‘, no weighting, consider each replicate Y 
value as an individual point). The regression was based on the four-parameter logistic Hill 
equation (see Equation 3-1 and Fig. 3-2) [74]. 
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Equation 3-1 
 
X  concentration 
Y  absorption 
Bottom value for Y for the minimal curve asymptote 
Top  value for Y for the maximal curve asymptote 
LogEC50 logarithm of drug concentration producing half maximal effect 
Hillslope steepness of concentration e response curve 
 
Fig. 3-2 Schematic diagram of the used Hill equation (adapted from [74]). 
In this project the MTT assay was used to assess the resistance factor of resistant cell lines 
(HCT-8ox, A2780cis). To avoid variation between different 96-well plates the corresponding 
cell pair was seeded out on the same plate (see Fig. 3-3). EC50 values, the concentration 
necessary to eradicate half of the cell population, were computed as described above and the 
resistance factor was calculated by dividing the EC50 value of the resistant cells by the EC50 
value of the respective sensitive cells.  
Y = Bottom +
Top – Bottom
1 +
Hill slope10LogEC  50
10X
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Fig. 3-3 96-well plate as prepared for assessing the resistance factor of A2780cis by the MTT 
 assay. Darker colors symbolize higher concentrations of the platinum complex tested. 
 Note that low concentrations of the platinum complex correspond to intense purple 
 and high concentrations to light purple color after incubation with MTT solution and lysis 
 with DMSO.  
The assay was also used to test the influence of the MRP modulator Gü83 and the GSH 
depletor BSO on the cytotoxicity of platinum complexes. In this case the cells were co- and/or 
preincubated with the relevant compound and the platinum complex. In this case cells 
cultivated under control conditions (without co- or preincubation) and under experimental 
conditions (co- or preincubation) were seeded out on the same plate.  
For Gü83 and BSO the assay was also used to assure that concentrations used in experiments 
were not cytotoxic. The assay was performed as described and cells were incubated with 
various concentrations of the respective compound either for 72 h or shorter. If the assay was 
performed to test the cytotoxicity after a shorter incubation time, cells were incubated with 
the compound for the chosen time span and subsequently incubated with cell culture medium 
until they were incubated 72 h altogether.  
3.6 Glutathione quantification 
To further investigate the role of GSH in platinum resistance an assay for determination of 
total cellular GSH was cross-validated based on bioanalytical guidelines [75,76]. The assay 
was based on the derivatization of reduced GSH with naphthalene-2,3-dicarboxaldehyde 
(NDA) to a fluorescent isoindole adduct (see Fig. 3-4, λexc at 472 nm and λem at 528 nm) [77].  
A2780 
A2780cis 
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Fig. 3-4 Reaction of GSH and NDA to a fluorescent isoindole adduct. 
GSH assay based on determination after sample derivatization and separation via capillary 
electrophoresis (CE) or high-performance liquid chromatography (HPLC) were described and 
validated [77-79] as well as a semi-quantitative determination without sample separation in 
96-well plates [80]. Allowing higher sample throughput an assay in 96-well plates was chosen 
for this project.  
Total cellular GSH comprises the reduced (GSH), the oxidized (GSSG) and the protein-bound 
(GSS-protein) form. Hence reduction of oxidized and protein-bound GSH using dithiothreitol 
(DTT) was necessary prior to derivatization with NDA (see Fig. 3-5). Results of the 
validation are presented in chapter 4.2.1. 
 
Fig. 3-5 Reduction of disulfides using DTT (pH > 7). 
3.6.1 Cell lysis 
Cells were seeded out in 6-well plates and allowed to attach overnight. After incubation with 
drugs/modulators, the cells were washed with PBS and detached using trypsin-EDTA 
solution. After adding cell culture medium the cells were transferred into an Eppendorf tube. 
Cells were centrifuged (167 g, 4 °C, 1 min) and resuspended in 1.0 mL PBS. 20 µL of the cell 
suspension was taken out twice for protein determination and the suspension was centrifuged 
again (167 g, 4 °C, 1 min). The cell pellet was washed with 1 mL of PBS again and 
2 H2O
2
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centrifuged (167 g, 4 °C, 1 min). The supernatant was then removed and the cell pellet lysed 
with 1.0 mL ice-cold perchloric acid (3.3%) followed by intensive vortexing for 10 seconds 
Afterwards the lysate was separated from the cell relict by centrifugation (12000 g, 4 °C, 
10 min). The supernatant was transferred into a new Eppendorf tube and stored at -80 °C until 
GSH determination. 
3.6.2 Glutathione determination 
To generate a calibration curve six standard solutions and three quality control (QC) samples 
were freshly prepared by diluting GSH working solutions (WS) 1 and 2 with perchloric acid 
(3.3%) as shown in Tab. 3-1. The stock solution used for preparation of WS1 and WS2 for 
QC samples was different from the stock solution used for preparation of WS1 and WS2 for 
the calibration curve. Standards and QC samples were not prepared using the matrix of the 
samples, lysed cell pellet, as lysed cell pellet itself contains GSH.  
Samples were carefully thawed on ice and 90 µL of each sample, standard solution and QC 
samples were pipetted on a 96-well plate. Standard solutions were measured in triplicate, QC 
samples and samples with unknown content in duplicate. For pH adjustment 50 µL of 1 M 
sodium hydroxide and 100 µL borate buffer pH 9.2 were added to each well. 10 µL of DTT 
solution was added for reduction of bound and oxidized GSH and the mixture was allowed to 
react for 2 min. Finally, 25 µL of NDA solution was added and the plate shaken softly for 
15 min. The fluorescence signal was then measured using a Fluoroskan Ascent
®
 microtiter 
plate reader (λexc 485 nm and λem 538 nm). If the fluorescence signal of a sample was above 
the calibration range the sample was diluted with perchloric acid (3.3%) and GSH 
determination was repeated. 
The calibration curve was generated using a weighting factor of 1/x
2
 using MVA
®
 2.0 
software and the concentration of the samples was calculated. When performing the assay the 
calibration curve was accepted when at least four out of the six calibration standards did not 
deviate more than 15% from their nominal values (20% for the lower limit of quantification) 
and when two out of three QC samples were within 15% of their nominal values (20% for 
lowest QC sample). The concentrations obtained were related to the protein contents of the 
samples to adjust for different cell volumes or sample loss during processing. The 
intracellular GSH content was expressed relative to the respective mean value for HCT-8. 
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Tab. 3-1 GSH-containing standard solutions and quality control samples for GSH determination. 
 GSH content  
[µM] 
GSH WS 1 
[µL] 
GSH WS 2 
[µL] 
Perchloric acid (3.3%) 
[µL] 
Standard solutions 
S1 1 - 100 900 
S2 2 - 200 800 
S3 5 - 500 500 
S4 10 - 1000 - 
S5 15 150 - 850 
S6 20 200 - 800 
Quality control samples 
QC1 3 - 300 700 
QC2 12 120 - 880 
QC3 18 180 - 820 
3.6.3 Effect of platinum exposure on the cellular GSH content 
To investigate the effect of platinum complexes on cellular GSH content, cells were incubated 
with 100 nM oxaliplatin (HCT-8 and HCT-8ox) or 100 nM cisplatin (A2780 and A2780cis) 
for 24 h. Control cells were incubated with PBS only. Samples were taken after 0, 4, 8, 12 and 
24 h, GSH and protein content were determined as described above and in chapter 3.7, 
respectively.  
3.7 Protein quantification 
In some experiments determination of protein content of samples was necessary for 
normalization of results to correct for different cell volumes and growth behavior as well as 
for sample loss during preparation. Hence the protein concentration was assessed using the 
bicinchoninic assay (BCA protein assay kit) according to the manufacturer’s instructions. The 
assay is based on the reduction of Cu
2+
 to Cu
+
 by proteins. Two molecules of bicinchoninic 
acid react with one Cu
+
 forming a purple chelate complex. The absorbance of the purple 
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chelate complex at 562 nm is proportional to the concentration of this complex as well as to 
the concentration of proteins and was determined using a UV microtiter plate reader. 
The method was validated in our working group with respect to sample preparation and with 
respect to the generation of the calibration curve (linearity and working range, precision and 
accuracy, lower limit of quantification) previously [70,81]. 
3.7.1 Standard solutions and quality control samples 
Standard solutions and quality control (QC) samples were prepared by dilution of a 2 mg/mL 
solution of bovine serum albumin (BSA) provided by the manufacturer. 
Tab. 3-2 Standard solutions and quality control samples for protein determination. 
 Volume BSA 
[µM] 
Volume ultrapure water 
[µL] 
Protein concentration 
[µg/mL] 
Standard solutions 
S1 50 1950 50 
S2 75 1925 75 
S3 100 1900 100 
S4 200 1800 200 
S5 300 1700 300 
S6 400 1600 400 
Quality control samples 
QC1 150 1850 150 
QC2 250 1750 250 
QC3 350 1650 350 
3.7.2 Sample preparation 
At first, 10 µL of 1 M sodium hydroxide was added to 20 µL of each sample for protein lysis. 
The protein samples were then sonicated at room temperature for 30 min. Afterwards samples 
were neutralized with 10 µL 1 M HCl. Samples were diluted with ultrapure water to be within 
the calibration range if necessary. Standard solutions and QC samples were treated in the 
same way except the dilution step.  
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The solutions were then transferred to a 96-well plate pipetting 20 µL of samples and QC 
samples in duplicate and standard solutions in triplicate. Afterwards a 50:1 mixture of BCA 
working reagent A (containing BCA) and BCA working reagent B (containing CuSO4) was 
prepared, 200 µL of the mixture was added to each well and the plate was incubated for 1 h at 
60 °C. UV absorbance at 570 nm was then determined using a Multiskan Ascent
®
 microtiter 
plate reader.  
Linear regression was performed using Microsoft
®
 Excel 2007 and sample concentrations 
were calculated from the regression curve. The calibration was accepted when at least four of 
the standard solutions did not deviate more than 15% from the nominal value (20% at the 
lower limit of quantification) and two of three QC samples did not deviate more than 15% of 
the nominal value.  
3.8 Mass spectrometry 
By the use of mass spectrometry (MS) the mass-to-charge ratio (m/z) of charged molecules 
can be detected and chemical structures of molecules can be proposed based on characteristic 
isotope patterns of single ions. The technique can be used for qualitative and/or quantitative 
analysis. Samples are vaporized, ionized, the ions separated by the ‘mass analyzer’, their 
signals detected and the signal processed into a mass spectrum. Ionization of the samples is 
performed in the ‘ion source’ and can be achieved by ‘electrospray ionization’ (ESI). The 
basic installation used for electrospray ionization mass spectrometry (ESI-MS) is depicted in 
Fig. 3-6. To further elucidate chemical structures, fragmentation techniques can be applied 
when using tandem mass spectrometry, which involves multiple MS steps. First specific 
‘masses’ are separated and then fragmented in a collision chamber. The fragments obtained 
are analyzed and can verify a molecular structure suggested.  
 
Fig. 3-6 Basic composition of an ESI-MS system (adapted from [82]). 
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To characterize platinum-glutathione adducts cisplatin and oxaliplatin were incubated with 
GSH in a ratio of 1:10 (55 μM platinum complex and 550 μM GSH) in an aqueous solution. 
Methanol, to permit vaporization (final concentration of 60%) and formic acid, to produce 
ions (final concentration of 1%), were added immediately or after a 12 h incubation time at 
37 °C. Subsequently, ESI-MS measurements were performed after static sample application 
using an ESI-quadrupole time-of-flight mass spectrometer (ESI-Q-qTOF, type: QSTAR XL) 
equipped with a nanospray ion source. Spectra were collected in positive mode over m/z 
range of 200 to 2000. Analyst
®
 QS software was used for analysis of spectra obtained. For 
these experiments the MS equipment of the working group of Dr. Sabine Metzger at the 
University of Düsseldorf, Germany, was used. 
3.9 Platinum accumulation 
To investigate the cellular platinum accumulation, 10
6
 HCT-8 or HCT-8ox cells were allowed 
to attach in 6-well plates for 12 to 14 hours. When the effect of buthionine sulfoximine (BSO) 
was investigated, cells were incubated with 100 µM BSO directly after being seeded out. 
Cells were then incubated with oxaliplatin [100 µM] and in some experiments additionally 
with MRP-modulating substances. Cells were harvested using trypsin-EDTA solution after 
washing with ice-cold PBS and resuspended in medium. The suspension was centrifuged, the 
supernatant removed and the cell pellet washed with 1 mL PBS twice. The cell pellet was 
lysed in 65% nitric acid (1 h, 80 °C) and the platinum content was quantified using flameless 
atomic absorption spectrometry (SpectrAA
®
 Zeeman 220) [83]. The platinum concentration 
was related to the protein content determined by the bicinchoninic acid (BCA) assay (see 
chapter 3.7).  
3.10 Platinum efflux 
The method chosen for measurement of platinum efflux was similar to the method used to 
assess platinum accumulation (see chapter 3.9). Cells were seeded out in 6-well plates, 
allowed to attach overnight and exposed for 2 h to 100 µM oxaliplatin alone or with 100 µM 
Gü83. Then cell culture medium was changed. At distinct time points cells were harvested 
after being washed with PBS twice. The samples were treated as described in chapter 3.9.  
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3.11 DNA platination 
As described in chapter 1.2.1 binding to DNA is an important feature in view of the 
mechanism of action of platinum complexes. Hence the influence of the MRP modulator 
Gü83 on DNA platination was also investigated. Cellular DNA was isolated and quantified, 
afterwards lysed and the amount of platinum bound was determined. The measurements were 
performed adapting a method previously published [84]. 
For the experiments 10
6
 HCT-8 or HCT-8ox cells were allowed to attach in 6-well plates for 
12 to 14 hours before they were incubated with oxaliplatin (100 µM) with or without 200 µM 
Gü83. Cells were harvested using trypsin-EDTA solution after washing with ice-cold PBS 
and resuspended in medium. The suspension was centrifuged and the cell pellet was washed 
with 1 mL PBS twice. The samples were stored at -20 °C until further analysis. 
DNA isolation was performed using a QIAmp
®
 DNA Mini Kit for solid-phase extraction 
according to the manufacturer’s instructions. The cell pellet was thawed, subsequently lysed 
by incubation with the protease solution and lysis buffer provided (10 min, 56 °C in ultrasonic 
bath) and finally isolated using the solid-phase extraction columns provided. Before lysis, the 
samples were treated with 4 µL ribonuclease A (RNase) solution [79]. Thereby ribonucleic 
acid (RNA) was cleaved and only DNA was isolated. DNA concentrations were measured by 
UV photometry [85].  
The solution of isolated DNA was desiccated using a centrifugal evaporator (6 to 8 h, 39 °C) 
and then lysed in 2 mL 1% nitric acid (24 h, 70 °C). The platinum concentration of the 
samples was determined by inductively coupled plasma mass spectrometry (ICP-MS) using a 
Varian 820 ICP-MS at the University of Essen, Germany. In brief, for determination by 
ICP-MS samples are ionized by inductively coupled plasma and then the ions of interest are 
separated and quantified by a mass spectrometer. Each ICP-MS analysis resulted from five 
replicate measurements consisting of 20 scans of the relevant isotopes. For platinum 
quantification the most abundant platinum isotope, Pt
195
, was chosen. Quality control samples 
and an internal standard were used to ensure the accuracy and precision of the measurements. 
The results were finally expressed as number of platinum atoms per million of nucleotides 
(Mnucleotides 330 g/mol). 
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3.12 SDS page and protein immunoblotting  
Immunoblots can be used to investigate gene expression on protein level. In this project this 
method was chosen for studying MRP2 protein levels using β-actin as housekeeping protein 
for normalization [86]. After separation of proteins by gel electrophoresis the proteins were 
transferred on a membrane using the western blot technique. The proteins adhering to the 
membrane were then detected using antibodies conjugated with horseradish peroxidase (HRP) 
resulting in a luminescence signal after addition of luminol [87]. 
3.12.1 Sample preparation 
Cells were seeded out in cell culture flasks (175 cm
2
) and cultivated to a confluence of about 
90%. For sample preparation cell culture medium was removed and cells washed with PBS 
once. To release the proteins of interest cell lysis was necessary. Hence 1 mL of lysis buffer 
containing the protease inhibitors leupeptin and pepstatin A (see 3.2.2) to prevent proteolysis 
was added to the cells and evenly distributed on the cell monolayer. Cells were scratched 
from the bottom of the flask using a cell scraper. The lysate was transferred into a reaction 
tube and shaken for 30 min at 4 °C to complete cell lysis. After centrifugation (12000 g, 4 °C, 
5 min) the supernatant was carried over into fresh reaction tubes for protein quantification (at 
20 µL each) and for immunoblot (at 100 µL each) keeping samples on ice all the time. The 
tubes were stored at -20 °C (protein quantification) and -80 °C (immunoblot) respectively. 
The amount of sample protein obtained was quantified using the bicinchoninic assay (see 
chapter 3.7). 
3.12.2 Gel electrophoresis and western blotting 
Separation of proteins according to size was performed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). Polyacrylamide gels were prepared freshly 
starting with the separating gel (10% acrylamide, see chapter 3.2.2), which was filled between 
two glass plates clamped in an appropriate fixture and covered with a layer of 100% 
isopropanol. After 15 min the stacking gel (see chapter 3.2.2) was added and a comb 
producing wells for sample application put in place. After 30 min the comb was removed and 
the fixture containing the gel was placed in an electrophoresis chamber (electrophoresis 
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equipment Mini-Protean
®
 II). Electrophoresis buffer was added till the gel was completely 
covered and the wells rinsed with buffer.  
Samples were diluted with loading buffer, which was supplemented with 5% dithiothreitol 
(DTT) solution (see chapter 3.2.2), to a concentration of 10 µg protein per 20 µL. Loading 
buffer contained SDS, which binds to proteins and allows their migration in an electric field 
as it is charged, and DTT, which is important for denaturation of proteins. Bromphenol blue 
was also added to make samples visible. The proportion of DTT containing loading buffer in 
the mixture, however, needed to be at least 50% to effectively prepare the samples. Otherwise 
the amount of protein obtained was too little and the sample could not be analyzed. After 
leaving the samples 30 min at room temperature, samples as well as a protein marker were 
pipetted into the wells of the gel. Afterwards the proteins were separated applying voltage 
(200 V) to the gel. Voltage was removed when the sample front reached the end of the gel. 
Prior to blotting proteins from the gel to a polyvinylidene fluoride (PVDF) membrane the 
membrane was treated with methanol for 20 seconds and shaken for 5 min in transfer buffer 
for equilibration. Afterwards the gel and the membrane were clamped tightly in a sandwich 
fixture and after that submerged in transfer buffer using the blotting equipment 
Mini-Protean
®
 II. Applying electric current (100 V, 350 mA, 60 min) allowed transfer of the 
proteins which still were electrically charged by sodium dodecyl sulfate (SDS) and thus 
bound to the membrane. Afterwards the membrane was shaken in tris-buffered saline (TBS) 
(see chapter 3.2.2). 
3.12.3 Visualization of proteins 
Before the proteins bound to the membrane were tagged with a primary antibody the 
membrane was shaken in blocking solution containing milk powder (see chapter 3.2.2) for 1 h 
to minimize unspecific binding of antibodies. The membrane was shaken three times for 
10 min with TBS-T solution subsequently. The solution of primary antibody against MRP2 
(see chapter 3.2.2) was added and the membrane was shaken for 1 h. The membrane was left 
overnight at 4 °C with the antibody solution left on it. The next morning the antibody solution 
was removed and poured into a centrifuge tube as it was conserved by addition of sodium 
azide for reuse. The membrane was shaken three times for 10 min with TBS-T solution 
subsequently and then shaken for 1.5 h with the solution of the secondary antibody (anti-goat) 
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conjugated to HRP. The solution was removed and discarded. The membrane was washed 
three times for 10 min with TBS-T solution while shaking. 
For visualization Pierce ECL Western Blotting Substrate was used. Luminol/enhancer and 
peroxide buffer were mixed 1:1 and 500 µL of the mixture were evenly distributed onto the 
membrane placed in a petri dish with the proteins upside. After 2 min the chemiluminescence 
signal generated by HRP and luminol was detected with the VersaDoc
™
 Imaging System and 
a digital image was produced. The digital image could be analyzed with the Quantity One
®
 
software.  
After washing the membrane with TBS-T solution the procedure was repeated using the 
solution of primary antibody against β-actin. The membrane was incubated with the solution 
of the primary antibody and shaken for 1 h but the incubation at 4 °C overnight was skipped. 
Again, a secondary antibody (anti-mouse) conjugated to HRP was used for visualization. 
3.13 Calcein assay 
The calcein assay was used to investigate the influence of modulators on the cellular efflux 
via MRP1, MRP2 or P-gp. The acetomethoxy derivate of calcein (calcein AM) can easily 
enter cells as it is very lipophilic. Inside the cell the methyl ester groups are cleaved by 
intracellular esterases resulting in fluorescent calcein. As calcein AM is a substrate of the 
efflux transporters MRP1, MRP2 and P-gp, inhibition of these transporters leads to an 
increase of the amount of calcein formed inside the cell [88]. Calcein itself is also a weak 
substrate of MRP1 and MRP2 but not of P-gp. To quench extracellular fluorescence by 
calcein, cobalt(II) sulfate was added. 
The assay was performed as described by Leyers [80]. For assessing the efflux, cells were 
suspended in Krebs HEPES buffer (KHP) and diluted to obtain a concentration of 3.33∙105 
cells/mL. 80 µL cell suspension were seeded out in each well of a 96-well plate and incubated 
with 10 µL of various concentrations of modulator substances for 30 min. Controls contained 
KHP only. Subsequently, 10 µL of cobalt(II) sulfate working solution and 33 µL of calcein 
AM working solution were added. The fluorescence signal was measured over 90 min using a 
FLUOstar
™
 OPTIMA microplate reader temperated at 37 °C (λexc 485 nm and λem 520 nm).  
The intensity of the signal was corrected for the intensity of the signal of the controls and 
plotted against time. In the time span investigated the increase of fluorescence can be 
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assumed to be a reaction of pseudo-zero order as the ester is abundant. For each concentration 
the slope was determined by linear regression. The slope was then plotted against the 
logarithmized concentrations of the respective substance. The efficacy of modulators in 
inhibiting the calcein efflux was expressed by the IC50 (half maximal inhibitory 
concentration) value, which indicates the amount of inhibitor needed to yield half of the 
maximal inhibitory effect. IC50 values could be obtained by non-linear regression 
(four-parameter logistic equation, see Equation 3-1) using the software GraphPad Prism
®
. 
3.14 Immunohistochemistry 
Proteins can be detected by immunocytochemical staining using specific binding of 
antibodies to antigens. In the experiments a primary antibody mapping within an N-terminal 
cytoplasmic domain of human MRP2 was used. The incubation with a secondary antibody, 
which was labeled with a fluorophore, binding the primary antibody allowed visualization of 
MRP2 using confocal laser scanning microscopy.  
For the experiments performed a protocol already established in the working group was 
used [21]. 2.5∙105 cells were seeded out in 2 mL medium on round cover slips in 6-well plates 
and allowed to attach for 36 h (37 °C, 5.5% CO2). Oxaliplatin stock solution was added to the 
medium to obtain a concentration of 100 µM and the cells were incubated for 2 h. Control 
samples were treated with an equivalent amount of PBS. Subsequently the medium was 
removed and the cover slips with the cells attached washed three times with PBS at room 
temperature. Cells were fixed on the cover slips by a 15 min treatment with 3.7% 
formaldehyde. After washing three times with PBS again cells were permeabilized by 
incubating with 0.02% Triton
®
 X-100 in PBS. To block unspecific binding sites 1% bovine 
serum albumin (BSA) in PBS was added for 60 min. Afterwards 50 µL of the primary MRP2 
antibody solution was pipetted directly on the cover slip. The cover slips were then covered 
with squared cover slips and the whole 6-well plate incubated for 90 min wrapped in a wet 
tissue and aluminum foil (37 °C, 5.5% CO2). After addition of 1 mL PBS the squared cover 
slips were removed and the round cover slips with the cells attached were washed with PBS 
twice. The cells were then incubated with the secondary antibody (Alexa Fluor
®
 488 goat 
anti-chicken IgG) proceeding as described above for the primary antibody. The nucleus was 
stained using DAPI which binds DNA. Therefore 1 mL PBS and 40 µL of DAPI working 
solution were added and left for 5 min. Finally the cover slips were washed with 70%, 90% 
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and 100% ethanol subsequently and fixed with mounting medium on microscope slides. 
Brightfield and fluorescence microscopy were performed using a Nikon Eclipse Ti 
microscope and NIS-Elements software. 
3.15 195Pt NMR spectroscopy 
Various experiments performed investigated the influence of Gü83 on cellular oxaliplatin or 
cisplatin accumulation. To investigate whether Gü83 binds to either oxaliplatin or cisplatin 
195
Pt NMR spectroscopy was applied. The platinum complexes were dissolved in a solution 
containing equal volumes of dimethylformamide (DMF) and PBS to obtain a concentration of 
10 mM each; Gü83 was dissolved in pure DMF (10 mM). The solutions were mixed 1:1 
leading to a concentration of 5 mM Gü83 and platinum complex each. The solvent of the final 
mixture, however, was thus composed of one quarter PBS and three quarter DMF. The 
platinum signal was followed over time by 
195
Pt NMR spectroscopy (Bruker DPX 300 
spectrometer). Spectra were calibrated related to K2PtCl4 at δ = -1.614 ppm. The 
measurements were performed at the working group of Prof. Jan Reedijk at Leiden University 
by Dr. Patricia Marqués Gallego. 
3.16 Statistical analysis 
3.16.1 Basic statistics 
Experiments were performed in triplicate and the mean was calculated from the dependent 
experiments. Usually the means of at least three independent experiments were calculated and 
the result represented as mean and standard deviation (SD) (see Equation 3-2 and 
Equation 3-3). 
n
x
 Mean
n
1i
i

 
Equation 3-2 
 
 xi:  individual measured values  
 n:  number of measurements 
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Equation 3-3 
 
 x :  mean value of all measurements  
 xi:  individual measured values  
 n:  number of measurements 
Experiments were performed with a small sample size. Hence data could not be tested for 
normal distribution. Assuming that means are normally distributed, the significance of 
differences between results was tested using a two-sided Student’s t-test. In case of dependent 
experiments the paired t-test and in case of independent experiments the unpaired t-test was 
used. If the significance of the influence of two independent variables on an outcome was 
investigated, two-way ANOVA with Bonferroni post-test was applied. In case p values were 
< 0.05 a difference between results was considered to be statistically significant; p values 
> 0.05 were considered not significant (n. s.).  
EC50 values describing cytotoxicity (see chapter 3.5) and IC50 values describing inhibitory 
concentration (see chapter 3.13) were assumed to be log-normally distributed [74]. Thus, the 
negative decimal logarithms (pEC50 and pIC50) were calculated and means were calculated 
from pEC50 and pIC50 values. For those experiments the standard error of the mean (SEM) 
was calculated to describe the accuracy of the determination of the mean (see Equation 3-4). 
n
SD
SEM 
 
Equation 3-4 
 n:  number of measurements 
When evaluating correlation between two variables the correlation coefficient, r, was 
calculated using MVA
®
 2.0. r indicates the strength and the direction of a linear relationship 
between two variables and is a value between -1 and +1. The closer the value is to either +1 
or -1, the stronger is the correlation. The algebraic sign indicates the direction of the 
correlation [89]. The statistical significance of r was calculated using a one-sided t-test. 
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3.16.2 Validation of the assay for GSH determination 
Accuracy 
The accuracy of a method describes how a determined concentration deviates from the true 
concentration of an analyte and is expressed as relative error (RE). For evaluation of RE the 
deviation between nominal and measured concentration was related to the nominal 
concentration (see Equation 3-5). Accuracy was calculated for several measurements on one 
day (within-day accuracy) and on different days (between-day accuracy). 
μ
100)μx(
 [%] RE


 
Equation 3-5 
 x :  mean value of all measurements  
 µ:  nominal value 
Precision 
The precision of a method specifies how individual measurements of the same sample of an 
analyte deviate from each other and is expressed as relative standard deviation (RSD). The 
RSD was calculated as shown in Equation 3-6. 
x
100SD
[%] RSD


 
Equation 3-6 
 x :  mean value of all measurements  
Recovery 
To determine recovery the signal of the spiked matrix was assessed as well as the signal of the 
unspiked matrix and the percentaged recovery computed according to Equation 3-7. 
c
100)c(c
[%]Recovery
us 

 
Equation 3-7 
 
 cs:  concentration measured in spiked matrix 
 cu:  concentration measured in unspiked matrix 
 c:  nominal concentration of the analyte in spiked solution 
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4 RESULTS 
4.1 Cytotoxicity and resistance factors 
Within the scope of this project the relevance of glutathione (GSH) and MRP-mediated efflux 
for platinum resistance was investigated. Thus, knowledge of the sensitivity of cells used in 
experiments towards platinum complexes is crucial. The sensitivity of the cell lines towards 
cisplatin and oxaliplatin was determined using the MTT assay (see chapter 3.5). On the basis 
of the EC50 values the resistance factor of the resistant variants of the cell lines was 
calculated. Both resistant cell lines were not only resistant to the platinum complex used for 
acquiring resistance but were also cross-resistant to the other platinum complex tested 
(resistance factor HCT-8ox/HCT-8: cisplatin 2.7, oxaliplatin 12.1; resistance factor 
A2780cis/A2780: cisplatin 5.6, oxaliplatin 4.0; see details in Tab. 4-1 and Appendix A).  
Tab. 4-1 Sensitivity of the cell lines used towards cisplatin and oxaliplatin investigated using an 
 MTT-based cytotoxicity assay (mean pEC50 ± SEM, n = 3-11). 
Cell line 
pEC50 (EC50) 
Cisplatin Oxaliplatin 
HCT-8 4.96 ± 0.10 
(11.0 µM) 
5.56 ± 0.06 
(2.8 µM) 
HCT-8ox 4.53 ± 0.12 
(29.5 µM) 
4.47 ± 0.05 
(33.9 µM) 
A2780 5.68 ± 0.08 
(2.1 µM) 
6.03 ± 0.26 
(0.93 µM) 
A2780cis 4.93 ± 0.07 
(11.7 µM) 
5.43 ± 0.14 
(3.7 µM) 
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4.2 The relevance of glutathione (GSH) for platinum resistance 
4.2.1 Validation of the assay for GSH determination 
As the focus of this project was on the impact of GSH in platinum resistance an assay for 
GSH determination (see chapter 3.6) was cross-validated based on the findings of Leyers and 
Zisowsky [79,80] and on bioanalytical guidelines [75,76]. The assay covered a calibration 
range from 1 to 20 µM GSH. 
Accuracy and precision 
For estimation of accuracy, samples with a known GSH content (3, 12, 18 µM) were 
determined several times on one day (within-day accuracy) and on different days (between-
day accuracy). The stock solution used for preparation of the samples was different from the 
stock solution used for preparation of the calibration curve. The accuracy of the individual 
measurements was within the acceptance level of ±15% determining various samples within a 
day (RE: -7.9 to 14.3%, accuracy of the means: RE: 3.2 to 6.2%, n = 6) and on different days 
(RE: -11.4 to 6.0%, accuracy of the means: RE: -0.7 to 1.5%, n = 5). Results can be seen in 
detail in Appendix B1. 
The precision of a method specifies how individual measurements of the same concentration 
of an analyte deviate from each other and is expressed as relative standard deviation (RSD). 
RSD could be calculated from the results gained from the samples analyzed for determination 
of accuracy. The precision was within the acceptance level of ±15% analyzing samples within 
a day (within-day precision) (RSD: 5.9 to 8.7, n = 6) and on different days (between-day 
precision) (RSD: 3.0 to 6.2, n = 5). Results can be seen in detail in Appendix B1. 
Recovery 
In order to assess the recovery of the assay, distinct amounts of GSH were added to cell lysate 
as biological matrix. The signal of the spiked matrix was assessed as well as the signal of the 
unspiked matrix and the difference used to calculate recovery (see chapter 3.16). Mean 
recovery was 45.5% and ranged from 42.6% to 48.0% (0.5 µM GSH: 48.0%; 3.33 µM 
GSH: 42.7%; 7.5 µM GSH: 46.0%, n = 3 each). 
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Linearity 
Correlation of the signal as a function of cell number was also tested. Mean correlation 
coefficient (r) was 0.9994 for HCT-8 (p < 0.05, t-test; values: 0.9989, 0.9999, n = 2), 0.9987 
for HCT-8ox cells (p < 0.05, t-test; values: 0.9981, 0.9992, n = 2), 0.9604 for A2780 
(p < 0.05, t-test; range: 0.9135 to 0.9995, n = 3) and 0.9957 for A2780cis cells (p < 0.05, 
t-test; values: 0.9920, 0.9993, n = 2), (see Fig. 4-1). Results can be seen in detail in 
Appendix B1. 
A 
 
B  
 
Fig. 4-1 Linearity of the fluorescence signal of the GSH-NDA adduct after lysis of different 
 numbers of A HCT-8 (filled symbols) and HCT-8ox (empty symbols) cells, B A2780 
 (filled symbols) and A2780cis (empty symbols) cells (symbols represent the mean of two 
 replicates, n = 2-3, (AU: arbitrary units)).  
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Calibration standard curve 
For generation of a calibration curve a series of samples with known concentrations of an 
analyte was measured and the relationship between signal and concentration was defined by 
regression. The lowest standard concentration of the calibration curve was 1 µM. At this 
concentration the response was 5.5 times higher than the fluorescence signal of a blank 
sample (perchloric acid 3.3% only) (blank (mean ±SD): 0.18 ± 0.004 arbitrary units (AU), 
n = 6; 1 µM: 0.99 ± 0.03 AU, n = 5). For cross-validation of the GSH assay six freshly 
prepared non-zero standard solutionss (1, 2, 5, 10, 15 and 20 µM) were analyzed on five days. 
Linear regression without and with weighting (1/x, 1/x²) of results were compared using the 
MVA
®
 software. The decision of the best model was based on the residual sum of squares 
(RSS). A small RSS is a sign of a good fit of the model to the data. As the RSS was lowest, 
weighting 1/x² was chosen for generation of the calibration curve for the assay (see Tab. 4-2). 
Results are shown in detail in Appendix B1. 
Tab. 4-2 Residual sum of squares (RSS) and correlation coefficient (r) of calibration curves  using 
 different weighting (n = 5). 
Weighting Unweighted  1/x  1/x² 
 
RSS r  RSS r  RSS r 
Mean  0.596 0.9994  0.082 0.9995  0.039 0.999 
Sum  2.981 -  0.411 -  0.196 - 
Accuracy and precision of the calibration standards were determined considering the results 
of five days. Accuracy was within the acceptance limit of ±15% (RE: -10.3 to 9.5%, accuracy 
of the means: RE: -3.3 to 3.5 %, n = 5) as well as precision (RSD: 2.3 to 4.8%, n = 5). Results 
can be seen in detail in Appendix B1. 
Stability of the GSH-NDA isoindole adduct 
GSH stock and working solutions as well as the NDA solution were freshly prepared when 
needed. As reported previously the fluorescent GSH-NDA isoindole adduct is not stable [77]. 
To find the optimal duration of the derivatization NDA solution was added to three solutions 
differing in GSH content and the fluorescence signal was detected over 50 min. As can be 
seen in Fig. 4-2 the signal of the adduct reached a plateau around a derivatization time of 
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15 min before decreasing; hence 15 min was chosen as derivatization time for the 
performance of the assay. 
 
Fig. 4-2 Fluorescence signal of the fluorescent GSH-NDA isoindole adduct after adding NDA to  
 0 (■), 1 (□), 10 (○) and 20 (●) µM GSH (AU = arbitrary units). Figure of a representative 
 experiment (symbols represent the mean of two replicates); (n = 3).  
Sample stability 
After sample production, performance of GSH determination can be delayed for days or 
weeks. To account for possible instability, even when samples were stored at -80 °C, stability 
of samples was assessed after 15 and 30 days of storage including one or two ‘freeze-and-
thaw’ cycles, respectively. Distinct numbers of cells were lysed in perchloric acid (3.3%) and 
the lysate was used for determination of baseline GSH content. Aliquots of the lysate were 
stored at -80 °C. At least two days before day 15 and day 30 samples for testing ‘freeze-and-
thaw’ stability were completely thawed at room temperature and refrozen afterwards. 
GSH proved to be stable in both scenarios in most cases when applying a deviation from 
baseline level < 15% as benchmark (see Tab. 4-3). However, the sample with the lowest GSH 
content thawed twice and stored for 30 days showed a deviation > 15%. Thus, repeated 
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‘freeze-and-thaw’ cycles were avoided in sample handling and samples were analyzed within 
30 days after generation. 
Tab. 4-3 Long-term stability and freeze-and-thaw stability of GSH in samples generated from 
 HCT-8 and HCT-8ox cells (GSH content [mM] ± relative change to baseline (day 0), 
 n = 1). 
  Long-term stability  Freeze-and-thaw stability 
 Day 0 Day 15 Day 30  Day 15 Day 30 
HCT-8 
      
4∙105 cells 2.6 2.9  
(+ 11.5%) 
2.4  
(- 7.7%) 
 2.8  
(+ 7.7) 
2.1 
(- 19.2%) 
8∙105 cells 5.5 5.9  
(+ 7.3%) 
5.8  
(+ 5.5%) 
 5.3  
(- 6.6%) 
4.7  
(- 14.5%) 
HCT-8ox 
      
4∙105 cells 6.8 7.2  
(+ 6.5%) 
7.0  
(+ 2.9%) 
 7.4  
(+ 8.8%) 
6.7  
(- 1.5%) 
8∙105 cells 16.9 17.4  
(+ 3.0%) 
15.8  
(+ 6.5%) 
 15.1  
(- 10.7%) 
16.1 
(- 4.7%) 
4.2.2 Cellular GSH content 
The GSH content of the two sensitive/resistant cell line pairs studied, namely 
HCT-8/HCT8-ox and A2780/A2780cis was determined after cell lysis and derivatization with 
NDA. As can be seen in Fig. 4-3 the content was the same in HCT-8 and HCT8-ox cells but 
was about 2.6 times higher in A2780cis compared to A2780 cells. The GSH content of the 
sensitive ovarian carcinoma cell line A2780 was significantly lower compared to the sensitive 
ileocecal colorectal adenocarcinoma cell line HCT-8 (p = 0.048) (see Appendix B2). 
Interestingly, the cell line with lowest GSH content (A2780) was also most sensitive towards 
cisplatin as well as oxaliplatin (see chapter 4.1). Despite their similar GSH content the three 
cell lines with higher GSH content differed in sensitivity towards the two platinum complexes 
investigated. 
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Fig. 4-3 Cellular GSH content related to the protein content in untreated cells (mean ± SD, n = 3, 
 unpaired t-test; n. s.: not significant). The mean value in HCT-8 cells was set to 100%. 
4.2.3 Effect of platinum incubation on the cellular glutathione content 
To investigate the effect of platinum complexes on cellular GSH content, cells were incubated 
with cisplatin or oxaliplatin for 24 h and GSH content was determined. Controls were 
incubated with PBS only. Samples were taken after 0, 4, 8, 12 and 24 h and GSH and protein 
content were assessed. A small increase in cellular GSH content was seen in HCT-8 and 
HCT-8ox cells with a quicker onset in the resistant variant. In A2780 cells the increase in 
cellular GSH was of a higher magnitude than in A2780cis cells. For statistical analysis of the 
results describing the effect of oxaliplatin or cisplatin on GSH content over time a two-way 
ANOVA was performed. According to the test results, incubation of cells with the platinum 
complexes did not significantly influence GSH content in the investigated cell lines over time. 
Only in A2780cis cells the influence of time on GSH content was significant (see Fig. 4-4, 
Fig. 4-5 and Appendix B2). 
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Fig. 4-4 Cellular GSH content related to the protein content (relative to baseline value) of 
 A HCT-8 and B HCT8-ox cells during incubation with (□) or without (■) 100 nM 
 oxaliplatin (mean ± SD, n = 3, two-way ANOVA did not show significant impact of time 
 and oxaliplatin). 
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Fig. 4-5 Cellular GSH content related to the protein content (relative to baseline value) of 
 A A2780 and B A2780cis cells during incubation with (□) or without (■) 100 nM 
 cisplatin (mean ± SD, n = 3, two-way ANOVA performed only showed significant 
 impact of time for A2780cis). 
4.2.4 GSH depletion 
To further elucidate the role of GSH with respect to platinum cytotoxicity and accumulation 
cellular GSH was depleted. For this purpose, buthionine sulfoximine (BSO), a GSH analogue 
reversibly inhibiting γ-glutamylcysteine synthetase (γGCS), the rate-limiting enzyme in GSH 
synthesis [24], was used. Cytotoxic effects of BSO in the concentrations used were excluded 
by the MTT assay. Those assays reveled that in HCT-8 and HCT-8ox cells a concentration up 
to 100 µM could be used for experiments (see Fig. 4-6). In preliminary experiments BSO was 
shown to reduce GSH levels in HCT-8 and HCT-8ox cells (Fig. 4-7).  
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Fig. 4-6 Cytotoxicity of BSO in HCT-8 (■) and HCT-8ox (□) cells assessed using the MTT assay 
 after incubation with various concentrations of BSO over 72 h; figure of one 
 representative experiment performed in triplicate (mean ± SD, n = 3).  
Investigating the effect of GSH depletion on oxaliplatin cytotoxicity a tendency to slightly 
higher pEC50 values of oxaliplatin (corresponding to lower EC50 values) could be observed 
but the effect was only statistically significant in HCT-8ox (Tab. 4-4). The cellular platinum 
accumulation was not affected by GSH depletion after 12 h incubation with 100 µM BSO as 
can be seen in Fig. 4-8. A difference in cellular platinum accumulation, however, was 
observed between the untreated controls of HCT-8 and HCT-8ox cells. Results are shown in 
Appendix B3 in detail. 
Tab. 4-4 Impact of GSH depletion induced by incubation with 50 µM BSO on oxaliplatin 
 cytotoxicity determined by the MTT assay (mean pEC50 ± SEM, n = 4-5). 
Cell lines 
pEC50 (EC50) 
 
+ BSO - BSO Paired t-test 
HCT-8 5.74 ± 0.17 
(1.8 µM) 
5.57 ± 0.19 
(2.7 µM) 
p = 0.0160 
HCT-8ox 4.47 ± 0.05 
(33.9 µM) 
4.37 ± 0.10 
(42.7 µM) 
p = 0.2372 
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Fig. 4-7 GSH depletion over time using A 50 µM and B 100 µM BSO in HCT-8 (■) and HCT-8ox 
 cells (□) (individual values, n = 2-4). The mean value in HCT-8 cells was set to 100%. 
 
Fig. 4-8 Cellular platinum accumulation related to protein content after 2 h incubation with 
 100 µM oxaliplatin with or without 12 h preincubation with 100 µM BSO (mean ± SD, 
 n = 5, paired t-test; n. s.: not significant). 
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4.2.5 Platinum-glutathione adducts 
In literature it is widely acknowledged that intracellularly formation of platinum-GSH adducts 
takes place (see chapter 1.4.1). Within the scope of this project the question whether platinum 
complexes form platinum-glutathione (GSH) adducts was addressed. First, a literature search 
for previously described adducts was performed (see Appendix C1 and C2). Eight adducts 
were found after incubation of cisplatin and GSH solutions (adduct 1 to 8) [35,41,90-96]; one 
adduct, adduct 3, was also identified in L1210 leukemia cells [35]. Two adducts (adducts 9, 
10) were found after incubation of oxaliplatin and GSH solutions and rat blood [97]. To 
facilitate the identification of adducts in mass spectrometry (MS) spectra isotope patterns of 
the adducts were created in silico with an online isotope distribution calculator (available at 
www.sisweb.com/mstools/isotope.htm); to give an example the isotope pattern for adduct 1 is 
shown in Appendix C3.  
Mixtures of platinum complexes and GSH solutions were prepared and screened for platinum-
GSH adducts using electrospray ionization (ESI)-MS (see chapter 3.8). The MS spectra 
obtained were screened for patterns characteristic for platinum-containing molecules. It was 
taken into account that adducts were protonated as formic acid had been added to the samples. 
Two cisplatin-GSH adducts were identified in this setting shortly after mixing the solutions 
and after 12 h incubation time at 37 °C. The MS spectrum as well as the chemical structures 
suggested are shown in Fig. 4-9. 
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Fig. 4-9 ESI-MS spectrum of cisplatin-GSH adducts recorded shortly after aqueous solutions of 
 GSH and cisplatin were mixed. The suggested structures for the signals a (adduct 2) and c 
 (adduct 1) are shown. Signal b might be the adduct seen in c (adduct 1) but with an –NH3 
 group (mass difference 17) missing. 
An oxaliplatin-GSH adduct was not found directly. However, when a signal showing a typical 
platinum pattern at m/z 704 was fragmented, adduct 9 (see Appendix C2) could be identified 
among the fragments at m/z 614. The signal at m/z 704 was probably produced by adduct 9 
with one molecule oxalic acid bound to it as the mass difference 90 corresponds to one 
molecule of oxalic acid. Before binding to the adduct oxalic acid was presumably separated 
from oxaliplatin while mixing the substances or during the process of ESI. The spectrum is 
shown in Fig. 4-10 B. The adduct was found shortly after mixing the solutions as well as after 
12 h incubation time at 37 °C. 
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Fig. 4-10 ESI-MS spectrum recorded shortly after aqueous solutions of GSH and oxaliplatin were 
 mixed showing the spectrum obtained after fragmentation of the signal at m/z 704 
 (signal c). A shows m/z from 300 to 800; in B the m/z area around signal b is enlarged 
 and a possible structure of an adduct is presented. Signal a results from unbound 
 oxaliplatin. 
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4.3 The relevance of MRP2 for platinum resistance 
The transport of endo- and exogenous substances as GSH adducts via MRP transporters has 
been frequently suggested. It is widely acknowledged that these efflux transporters are of 
importance in platinum resistance as well. This project focused on MRP2, as there is most 
evidence for its involvement among all MRP (see chapter 1.5.1). 
4.3.1 Protein expression 
At first the expression of MRP2 on the protein level was investigated in the cell lines used 
using SDS page and immunoblot (see chapter 3.12). A representative immunoblot is shown in 
Fig. 4-11. β-Actin expression was also assessed as it was selected as housekeeping marker for 
normalization. As shown in Fig. 4-12 the MRP2 expression was in the same range in HCT-8 
and HCT-8ox cells. MRP2 was not detected in A2780 but was expressed on a low level in 
A2780cis cells. In HCT-8 and HCT-8ox cells the experiments were also performed after 12 h 
incubation with 10 µM oxaliplatin. In these experiments the expression was increased in 
HCT-8 (not significantly) but not in HCT-8ox cells. Results are shown in detail in 
Appendix D1. 
      MRP2 (190-200 kDa) 
      β-actin (42 kDa) 
A B C D E F  
Fig. 4-11 Immunoblot analysis of MRP2 and β-actin expression in A A2780, B A2780cis C HCT-8 
 and D HCT-8ox, Expression was also assessed in HCT-8 and HCT-8ox cells treated 
 with 10 µM oxaliplatin for 12 h (E, F). Figure of a representative immunoblot, n = 2-6). 
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Fig. 4-12 Expression of MRP2 normalized to β-actin in untreated cells and after treatment with 
 10 µM oxaliplatin for 12 h (mean ± SD, n = 2-6 (n = 2 only for A2780), unpaired t-test; 
 n. s.: not significant). 
Relationship between MRP2 expression and cytotoxicity of platinum complexes 
As described in chapter 1.5.1, MRP2 overexpression is associated with decreased sensitivity 
to platinum complexes. To check if this relationship can also be found in the cell lines used 
within this project expression data obtained (see chapter 4.3.1) was related to EC50 values of 
cisplatin and oxaliplatin, representing sensitivity to the platinum complexes (see chapter 4.1). 
As can be seen in Fig. 4-13 an association between MRP2 expression and sensitivity is 
apparent when considering A2780, A2780cis and HCT-8ox cells. HCT-8 cells, however, have 
EC50 values similar to A2780cis while showing highest MRP2 expression. 
 
Fig. 4-13 Relationship between MRP2 expression relative to β-actin and EC50 values of  
 cisplatin (■) and oxaliplatin (□) in A2780, A2780cis, HCT-8ox and HCT-8 cells (from 
 left to right). 
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4.3.2 Fluorescence microscopy 
Localization of MRP2 was assessed in HCT-8 and HCT-8ox cells by use of 
immunofluorescence microscopy (see chapter 3.14). To compare the localization in the 
sensitive and resistant cells after immunohistochemical staining cells were viewed in 
brightfield and with confocal laser scanning microscopy. As shown in Fig. 4-14 A to C 
immunofluorescence localization of MRP2 (green) was similar in both cell lines and 
distributed equally around the nuclei (blue). As already described by Buss HCT-8ox cells 
have a greater diameter than HCT-8 [70]. The localization of MRP2 was not altered after 2 h 
treatment with 100 µM oxaliplatin.  
HCT-8   
  
 
 
HCT-8ox   
   
 
Fig. 4-14 Microscopic images of HCT-8 and HCT-8ox cells after immunostaining of MRP2 and 
 staining of the nuclei using DAPI: A brightfield, B immunofluorescence localization of 
 MRP2 (green) overlay with brightfield and C immunofluorescence localization of MRP2 
 (green) with stained nuclei (blue). Scale bars represent 10 µM. 
  
A B C D 
A B C D 
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4.3.3 MRP modulation by Gü83 
The efflux of platinum complexes or their GSH adducts, respectively, has been described in 
literature but is still under debate (see chapter 1.6). To further clarify this issue, the effect of 
Gü83, a 4-aminobenzoic acid derivative modulating the efflux via MRP1 and MRP2, was 
studied (see chapter 1.5).  
To assure that Gü83 is not toxic in the concentration used in further experiments cell viability 
was tested using the MTT assay. No difference in cell viability expressed as absorbance was 
seen comparing untreated cells and cells treated with Gü83 (see Fig. 4-15). 
 
Fig. 4-15 Viability of cells after 4 h incubation with or without two different concentrations of 
 Gü83 assessed using the MTT assay (mean and individual values, n = 3, unpaired t-test; 
 n. s.: not significant). 
4.3.3.1 Chemical reaction of Gü83 with platinum complexes 
Platinum complexes are potential binding partners for molecules used in experiments for 
modulation of cellular platinum accumulation [98]. The following experiments were 
conducted to exclude binding of Gü83 to oxaliplatin or cisplatin. Therefore solutions of the 
respective complexes were mixed and the platinum signal followed over time by 
195
Pt NMR 
spectroscopy (see chapter 3.15). 
195
Pt shift strongly depends on surrounding ligands and thus 
any reaction of the respective platinum compound with Gü83 would result in an altered 
signal. As shown in Fig. 4-16, the platinum signal was not altered after addition of Gü83. 
Hence a chemical reaction of Gü83 with oxaliplatin as well as cisplatin could be excluded. 
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Fig. 4-16 
195
Pt NMR spectrum monitoring the reaction of Gü83 [5 mM] with A oxaliplatin [5 mM] 
 and B cisplatin [5 mM] in a DMF solution containing 25% PBS. 
4.3.3.2 Platinum accumulation upon oxaliplatin exposure 
To further address the question whether platinum complexes are excreted via MRP the impact 
of MRP inhibition by Gü83 on cellular platinum accumulation was assessed. The experiments 
were primarily performed using HCT-8 and HCT-8ox cells as MRP2 expression was 
confirmed in those cells. In the experiments performed, platinum accumulation increased as a 
consequence of MRP1 and MRP2 inhibition with Gü83 in a concentration-dependent manner 
upon incubation with oxaliplatin (see Fig. 4-17). It should be noted that Gü83 might be 
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cytotoxic in the two highest concentrations used as alterations in cell viability were only 
assessed up to 200 µM (10
-3.7
M) (see Fig. 4-15). As the solubility of Gü83 was limited higher 
concentrations could not be investigated. The effect was also seen when monitoring the 
influence of Gü83 [100 µM] on cellular platinum accumulation over 3 h (Fig. 4-18). For 
statistical analysis of the effect of Gü83 over time a two-way ANOVA was performed. 
According to the test results, time as well as incubation with Gü83 significantly influenced 
platinum accumulation in HCT-8 and HCT-8ox cells. Results are shown in detail in 
Appendix D2. 
 
Fig. 4-17 Cellular platinum accumulation related to protein content after 2 h incubation with 
 different concentrations of Gü83 and 100 µM oxaliplatin in HCT-8 (■) and HCT-8ox (□) 
 cells (mean ± SD if applicable; n = 1-5). 
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Fig. 4-18 Cellular platinum accumulation related to protein content after incubation with 
 DMSO (■) or 100 µM Gü83 in DMSO (□) and 100 µM oxaliplatin in A HCT-8 and B 
 HCT-8ox cells (mean ± SD, n = 3, two-way ANOVA showed significant impact of time 
 and Gü83 on platinum accumulation). 
4.3.3.3 Platinum accumulation upon cisplatin exposure 
Similar experiments were also performed using cisplatin in the same concentration as 
oxaliplatin before. The concentration of Gü83 [100 µM] and the duration of incubation (2 h), 
however, were not varied. Again a higher platinum accumulation was found in the cells 
coincubated with the MRP modulator (Fig. 4-19). The difference was statistically significant 
in HCT-8 cells (p < 0.05, paired t-test). For details see Appendix D2. 
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Fig. 4-19 Cellular platinum accumulation related to protein content after 2 h incubation with 
 100 µM Gü83 and 100 µM cisplatin (mean ± SD, n = 4-5, paired t-test; n. s.: not 
 significant). 
In Tab. 4-5 the changes in platinum accumulation induced by Gü83 are summarized and are 
expressed as a factor for illustration. The amount of platinum accumulated was generally 
higher in the case of cisplatin compared to oxaliplatin. The increase was in the same range for 
all cells but seems to be higher in the sensitive cells. Comparing the uptake in sensitive and 
resistant cells the difference is more obvious after oxaliplatin incubation than after cisplatin 
incubation. 
Tab. 4-5 Cellular platinum accumulation after 2 h incubation with 100 µM platinum complex and 
 100 µM Gü83. For clarification only means are shown, variablility is illustrated in  
 Fig. 4-18 and Fig. 4-19. 
 Platinum accumulation (platinum/protein [ng/µg], mean) 
Oxaliplatin Oxaliplatin 
+ Gü83 
Factor of 
increase 
Cisplatin Cisplatin  
+ Gü83 
Factor of 
increase 
HCT-8 0.34 0.54 1.6 1.34 2.18 1.6 
HCT8-ox 0.17 0.25 1.5 1.12 1.56 1.4 
HCT-8/ 
HCT-8ox 
2 2.2  1.2 1.4  
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The impact of Gü83 on cellular platinum accumulation after incubation with cisplatin was 
also investigated in A2780 and A2780cis cells. As described by Zisowsky et al. the platinum 
accumulation was significantly lower in the cisplatin-resistant cells in the control experiments 
(see Fig. 4-20) [99]. In the resistant cells a small but not significant increase was observed 
when Gü83 was added (p > 0.05, paired t-test). In the sensitive cells even a small but not 
statistically significant decrease was observed (p > 0.05, paired t-test). Data are shown in 
Appendix D2. 
  
Fig. 4-20 Cellular platinum accumulation related to protein content after 2 h incubation with 
 100 µM Gü83 and 100 µM cisplatin (mean ± SD, n = 3, paired t-test). 
4.3.3.4 Platinum efflux 
Platinum accumulation comprises platinum uptake and platinum efflux. The latter was also 
addressed experimentally. Platinum efflux was assessed similar to platinum accumulation. 
After a certain time of incubation with oxaliplatin with or without Gü83 the cell culture 
medium was replaced with a platinum-free medium. Samples were taken at certain time 
points (for details see chapter 3.10). In Fig. 4-21 the platinum accumulation at these time 
points is illustrated. Platinum decrease over time demonstrates the efflux. No impact of Gü83 
on efflux was observed in HCT-8 cells over the time period studied. For statistical analysis of 
the results describing the effect of Gü83 over time a two-way ANOVA was performed. 
According to the results incubation with Gü83 did not significantly influence platinum efflux 
in HCT-8 and HCT-8ox cells. Time had only an effect in HCT-8 cells. Results are shown in 
detail in Appendix D2. 
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Fig. 4-21 Platinum efflux illustrated as cellular platinum content in HCT-8 (■/□) and HCT-8ox 
 (●/○) after 2 h incubation with 100 µM oxaliplatin without (filled symbols) or with 
 100 µM Gü83 (empty symbols) over time after replacing cell culture medium  
 (mean ± SD, n = 3, two-way ANOVA showed significant impact only for time in 
 HCT-8 cells). 
4.3.3.5 DNA platination 
As described above, an effect of Gü83 on platinum accumulation could be shown. DNA 
platination is important for the mode of action of platinum complexes. Hence the influence of 
Gü83 on this intracellular target was investigated as well. The results shown in Fig. 4-22 
illustrate that coincubation of Gü83 led to an increase in DNA platination. The increase was 
statistically significant only in the sensitive cells (unpaired t-test). 
In Fig. 4-23 the association between DNA platination and cellular platinum accumulation is 
depicted considering all values without differentiation of cell-type and treatment. It seems that 
lower cellular platinum content effects DNA platination stronger compared to higher cellular 
platinum content. Data are shown in Appendix D2. 
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Fig. 4-22 DNA platination after 3 h incubation with 200 µM Gü83 and 100 µM oxaliplatin 
 (mean ± SD, n = 3, unpaired t-test). 
 
 
Fig. 4-23 Association of DNA platination and cellular platinum accumulation after 3 h 
 incubation and 100 µM oxaliplatin in HCT-8 (■) and HCT-8ox cells (□) and after 
 coincubation with 200 µM Gü83 (HCT-8 ((●) and HCT-8ox cells (○); n = 3. 
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4.3.3.6 Effects of indometacin and ciclosporin on platinum accumulation 
So far an effect on cellular platinum accumulation was studied using the MRP modulator 
Gü83. To exclude that this effect is not due to specific properties of Gü83 the influence of 
further MRP modulators on platinum accumulation was investigated. Substances used were 
the non-steroidal anti-inflammatory drug indometacin and the immunosuppressant 
ciclosporin. Both substances led to an increase in cellular platinum accumulation, which was 
only statistically significant for ciclosporin in HCT-8 cells (Fig. 4-24 and Fig. 4-25). 
Ciclosporin showed only a marginal effect in HCT-8ox cells. For detailed results see 
Appendix D2.  
For indometacin a higher concentration was chosen [200 µM] than for Gü83 and ciclosporin 
[100 µM each] as IC50 values for MRP1 and MRP2 inhibition are higher in case of 
indometacin [54].  
 
Fig. 4-24 Cellular platinum accumulation related to protein content after 2 h incubation with 
 200 µM indometacin and 100 µM oxaliplatin (scatter blot of individual values and mean, 
 n = 3, paired t-test; n. s.: not significant). 
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Fig. 4-25 Cellular platinum accumulation related to protein content after 2 h incubation with 
 100 µM ciclosporin and 100 µM oxaliplatin (scatter blot of individual values and mean, 
 n = 3, paired t-test; n. s.: not significant). 
4.3.3.7 Comparative potency of MRP modulators 
As an influence of MRP inhibition on cellular platinum accumulation was observed, it was 
interesting to reveal if HCT-8 and HCT-8ox cells can functionally excrete substances via 
MRP and/or P-gp and if the effect on platinum accumulation shown was indeed due to MRP 
inhibition. For this purpose, the calcein assay was performed (see chapter 3.13). The calcein 
assay can be used to investigate the efflux via MRP1, MRP2 and P-gp and the influence of 
modulators on cellular efflux. The assay is not specific for any of the three transporters and 
the results summarize the effect of the three transporters together. In Fig. 4-26 and Fig. 4-27 
the results of the calcein assay using various concentrations of the modulators are shown. The 
term ‘response’ represents the slope of the increasing calcein fluorescence signal that was 
determined by linear regression. For the MRP modulator Gü83 (Fig. 4-26) a sigmoidal dose-
response curve was obtained. Hypothesizing that oxaliplatin might be a substrate of MRP and 
as such compete with the substrate calcein, the assay was also performed using oxaliplatin. 
The platinum complex, however, did not have an effect on the slope of the calcein 
fluorescence signal (Fig. 4-26).  
  
HCT-8 HCT-8 HCT-8ox HCT-8ox
0.0
0.5
1.0
1.5
2.0
+ ciclosporin + ciclosporin
p < 0.05
n. s.
P
la
tin
u
m
/p
ro
te
in
 [
n
g
/µ
g
]
RESULTS 
76 
 
 
A 
 
B 
 
Fig. 4-26 Calcein efflux after incubation of HCT-8 (■) and HCT-8ox (□) cells with 0.3 µM 
 calcein AM and different concentrations of A Gü83 and B oxaliplatin (response = slope; 
 A: mean ± SD, n = 3 B: absolute values, representative graph, n = 3). 
The previous experiments implied an effect of the MRP modulators indometacin and 
ciclosporin on platinum accumulation after incubation with oxaliplatin. The influence of these 
substances on calcein efflux was also investigated using various concentrations of the 
modulators (Fig. 4-27). 
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Fig. 4-27 Calcein efflux after incubation of HCT-8 (■) and HCT-8ox (□) cells with 0.3 µM 
 calcein-AM and different concentrations of A ciclosporin and B indometacin
 (response = slope, mean ± SD, n = 3). 
From the concentration-response curves the IC50 values were estimated with four-parameter 
logistic non-linear regression using the software GraphPad Prism
®
 (see Tab. 4-6). The values 
give an idea about the concentration which is effective in inhibiting MRP1, MRP2 and P-gp 
in HCT-8 and HCT-8ox cells. Ciclosporin was most and indometacin least effective in 
inhibiting calcein efflux in HCT-8 and HCT-8ox cells. Results of individual testing days are 
shown in Appendix D3. 
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Tab. 4-6 pIC50 values of MRP modulators derived from calcein efflux experiments (mean 
 pIC50 ± SEM, n = 3). 
 
pIC50 (IC50) 
HCT-8 HCT-8ox 
Gü83 5.21 ± 0.34 
(6.2 µM) 
4.76 ± 0.20 
(17.4 µM) 
Indometacin 3.68 ± 0.36 
(208.9 µM) 
4.00 ± 0.16 
(100.0 µM) 
Ciclosporin  5.78 ± 0.27 
(1.7 µM) 
5.75 ± 0.15 
(1.8 µM) 
4.3.3.8 Effect of Gü83 on cytotoxicity 
As MRP modulators have an effect on cellular platinum accumulation and DNA platination 
they could as well alter the sensitivity of cells towards platinum complexes. To test this 
hypothesis the MTT assay (see chapter 3.5) was performed with oxaliplatin in the presence 
and absence of Gü83. It was found that EC50 values increased when cells were coincubated 
with 100 µM Gü83 as can be seen in Tab. 4-7. The effect was found to be significant in 
HCT-8 cells. For results in detail see Appendix D4. 
Tab. 4-7 pEC50 of oxaliplatin with or without coincubation with 100 µM Gü83 (mean 
 pEC50 ± SEM, n = 4, paired t-test). 
Cell lines 
pEC50 (EC50) 
 
+ Gü83 - Gü83 p value 
HCT-8 5.35 ± 0.09 
(4.5 µM) 
5.45 ± 0.08 
(3.5 µM) 
0.027 
HCT-8ox 4.62 ± 0.22 
(24.0 µM) 
4.84 ± 0.11 
(14.4 µM) 
0.146 
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5 DISCUSSION 
In chapters 5.1 and 5.2 the investigations with regard to GSH and MRP-mediated efflux are 
reviewed. The implications of the results with regard to the interaction between GSH and 
MRP in platinum resistance are discussed in chapter 5.3. As a final point the clinical 
relevance of the findings is highlighted in chapter 5.4. 
5.1 Glutathione and platinum resistance 
5.1.1 Assay for GSH determination 
This project aimed at further elucidating the impact of GSH on platinum resistance. To 
address the investigations on GSH, an assay for GSH determination was established and 
validated. Most assays for GSH determination previously described were performed by high-
performance liquid chromatography (HPLC) or capillary electrophoresis (CE) which are 
characterized by low detection levels and selectivity [78,100-103]. In this project a semi-
quantitative 96-well plate-based assay was chosen to allow high sample throughput. 
The assay was adapted from a naphthalene-2,3-dicarboxaldehyde (NDA)-based assay 
validated for GSH determination using yeast cells [77], which has also been applied in other 
cell models [80]. As originally yeast cells were used and a different calibration range was 
chosen (0.3 to 6.5 µM by Lewicki et al. vs. 1 to 20 µM in this project) the assay was adapted 
and extensively validated. Validating the assay, accuracy and precision were according to the 
requirements [75,76]. For generation of the calibration standard curve a weighted calibration 
(1/x
2
) was shown to go along with smallest residues and was chosen for the assay. The GSH 
content was related to the protein content of the sample to account for sample loss during 
performance of the assay, different cell growth over time and different cell sizes [104]. 
The relatively low recovery found (around 45%) could be due to the matrix effect of the cell 
pellet as higher amounts of perchloric acid in cell lysis were reported to correlate with higher 
recovery [77]. The volume of perchloric acid was not increased as a fast sample processing 
was more feasible using 1 mL only. The cell number was either not reduced as otherwise the 
GSH content would have been too low in the lysate generated especially from A2780 cells. 
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However, as the volume of perchloric acid was reported to be decisive, strictly 1.0 mL of 
perchloric acid was used and the linearity of the fluorescence signal for GSH extracted from 
different cell numbers was tested and verified. Hence effects of the cell mass/perchloric acid-
ratio on the amount of GSH determined can be excluded. To account for the low recovery, the 
results of the determination of GSH content were expressed as relative values either related to 
baseline value or related to the respective mean value for HCT-8. 
Selectivity has not been investigated in this project. Lewicki et al. tested the assay on different 
thiols (GSH, GSSG, γ-glutamylcysteine, cysteinylglycine, cysteine, homocysteine, 
thioglycolic acid, DTT, dithionite) and found significant fluorescence signals only for GSH 
and its precursor γ-glutamylcysteine. The latter is the precursor of GSH in its de novo 
synthesis exhibiting low levels in eukaryotic cells. Thus, this finding has only little impact on 
GSH determination [77].  
5.1.2 Cellular GSH content 
The cellular GSH content of the four human cancer cell lines investigated in this project was 
determined. In A2780cis cells, the variant resistant to cisplatin, the cellular GSH content is 
increased compared to A2780 cells, as has been described for cisplatin-resistant and 
oxaliplatin-resistant cells repeatedly [25,29,30,105,106]. On the contrary, there was no 
difference in GSH content related to the protein content in HCT-8 cells and the oxaliplatin-
resistant variant HCT-8ox cells. Considering the results of all cell lines, it is obvious that the 
cellular GSH content is similar in HCT-8, HCT-8ox and A2780cis but is lower in A2780 
cells. Considering all cell lines there is no relationship between GSH content and the 
sensitivity to cisplatin and oxaliplatin. The findings are in agreement with previous studies as 
no correlation between total GSH content and sensitivity to cisplatin, carboplatin and 
oxaliplatin was found investigating a variety of diverse human cancer cell lines [56,107,108]. 
It is, however, noteworthy that the cell line with the lowest GSH content, A2780, was most 
sensitive to cisplatin and oxaliplatin.  
Elevated GSH levels have been found in various types of cancer cells. The differences in 
basal GSH content among different cancer cells found in this and other projects [56,107] 
could be due to varying activities of intracellular pathways leading to increased GSH 
synthesis. Extracellular-signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK)-
mediated activation of activator protein 1 (AP-1) was found to increase cellular GSH content. 
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The change was described to be caused by altered expression of γ-glutamylcysteine 
synthetase (γGCS), the rate-limiting enzyme in GSH synthesis, as the region of DNA that 
initiates transcription of the γGCS gene, the γGCS promoter, contains recognition sites for 
AP-1 [109].  
Moreover, the activation of the antioxidant response element (ARE) by the transcription 
factor ‘nuclear factor erythroid 2-related factor 2’ (Nrf2) might account for increased GSH 
content. Nrf2 is negatively regulated by Kelch-like ECH-associated protein 1 (Keap1) but in 
case of oxidative or electrophilic stress Nrf2 translocates to the nucleus and activates ARE. 
ARE is located in the promoter region of diverse genes encoding for enzymes involved in 
phase I/phase II detoxification and GSH homeostasis like γGCS, GSH reductase and GSH 
peroxidase [110]. However, Nrf2 might also cause higher GSH synthesis by stimulating the 
pro-oxidative action of Bcl-2 family anti-apoptotic proteins. Bcl-2 activation can be followed 
by an increase of ROS produced by mitochondria. In consequence, the resulting oxidative 
stress environment could lead to an increased cellular GSH content. The mechanism, 
however, is not clear [25]. Over-expression of Bcl-2 has amongst others been reported to 
result in higher GSH content and to recruit GSH to the nucleus and thus to prevent apoptosis 
as nuclear GSH is important for glutathionylation of proteins and in consequence for the 
regulation of protein functions during the cell cycle [111]. As described in chapter 1.3.3 Bcl-2 
overexpression was associated with resistance to cisplatin in breast cancer cells [22] and also 
stable overexpression of Nrf2 was shown to result in resistance to cisplatin and 
downregulation of this factor in sensitization [112]. However, as increased GSH content was 
only associated with resistance in A2780/A2780cis cells a contribution of Nrf2 and Bcl-2 to 
resistance via GSH can only be assumed in this cell model.  
To further investigate if and how GSH is involved in detoxification of platinum complexes 
cellular GSH content was also determined after addition of oxaliplatin or cisplatin to the cells. 
Here only a tendency towards a small increase in cellular GSH content was seen in HCT-8, 
HCT-8ox and A2780cis cells. The increase in A2780 cells was more obvious but was not 
significant either. Interestingly, the response to a platinum complex with respect to GSH 
content was most evident in the cell line with lowest baseline GSH content, suggesting that 
the other cell lines already exhibit a high GSH content which cannot be increased any further. 
In human melanoma cells a change in reduced GSH content after addition of cisplatin (2 and 
5 µM for 3 and 6 h) was not seen either [113]. In contrast, in HCT-8 variants resistant to 
cisplatin a 6-fold increase in GSH was reported after cisplatin incubation [37]. These results 
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reflect the heterogeneity in data on GSH response to platinum complexes. The effect is 
probably dependent on cell type and baseline GSH content but could also differ among 
individual platinum complexes, as GSH content was not assessed after cisplatin incubation in 
HCT-8 and HCT-8ox cells but only after oxaliplatin treatment. Moreover, it has to be taken 
into consideration that non-toxic concentrations of the platinum complexes were used which 
could have been too low to observe a distinct effect on GSH content. 
5.1.3 Effects of GSH depletion 
The GSH-depleting agent buthionine sulfoximine (BSO) was used to further clarify the role 
of GSH in platinum resistance in HCT-8/HCT-8ox cells. BSO was reported to effectively 
reduce cellular GSH which was shown in HCT-8 and HCT-8ox cells in this project as 
well [113]. In different cell models accumulation of cisplatin was not altered after GSH 
depletion, corresponding to the findings of unchanged platinum accumulation after incubation 
with oxaliplatin in HCT8 and HCT-8ox cells [80,114]. In consequence, the cellular GSH 
content does not seem to be relevant for platinum accumulation upon oxaliplatin exposure in 
the cells investigated. 
Assuming that GSH is an important cytoprotectant in cancer cells, an augmented toxicity of 
platinum complexes would be the logical consequence of GSH depletion and has been 
observed in cell culture experiments [31,113,114]. In this study HCT-8 cells were sensitized 
by GSH depletion. The same tendency was also observed in the oxaliplatin-resistant cell line 
HCT-8ox but the effect was smaller and not significant. Hence results suggest that GSH 
depletion does not overcome oxaliplatin resistance.  
As GSH depletion was not associated with an altered platinum accumulation there must be 
other reasons for the sensitization towards oxaliplatin. The effect achieved could be due to the 
fact that less intracellular platinum is detoxified by GSH or to an inhibition of DNA repair in 
consequence of GSH depletion [115]. However, also disturbance of regulation of cell 
signaling involving protein S-glutathionylation and dysfunction of the cellular redox system 
are possible explanations for an increased sensitivity towards oxaliplatin [25,109]. 
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5.1.4 Platinum-glutathione adducts 
Formation of platinum-GSH adducts and transport out of the cell by transporters such as MRP 
is a widely recognized mechanism of platinum resistance [5,6,34,35]. In this project two 
platinum-GSH adducts for cisplatin und one for oxaliplatin were identified after incubation of 
the platinum complexes with GSH. The adducts, however, were not obtained from 
experiments with cells as the detection method was sensitive towards salts and the 
investigation of cell extracts would have required extensive extraction and purification steps. 
Thus, the structures identified can only serve as indicators for further studies with cells or 
cellular extracts. A separation step, like high-performance-liquid chromatography (HPLC), 
has not been performed prior to ESI and should be considered in future experiments as ESI-
MS, also coupled with liquid chromatography (LC), has been successfully used for detection 
of platinum complexes [116,117] and for identification of formation of aqua complexes of 
cisplatin [118]. Moreover, polynuclear platinum adducts were detected by using ESI-MS 
investigating the reaction of [Pt(L-methionine-S,N)Cl2] with GSH [119]. 
Research on putative intracellular GSH adducts is still ongoing and the state of knowledge is 
conflicting. Recently published results raise doubt about GSH as main intracellular binding 
partner of platinum complexes. When reviewing literature it appears that the identification of 
intracellularly formed platinum-GSH adducts from cell culture experiments has been reported 
only twice, with both research groups choosing similar analytical methods [35,37]. Ishikawa 
and Ali-Osman have isolated a putative platinum-GSH adduct from a mixture of cisplatin and 
GSH which they could identify in cell extract from cells incubated with cisplatin as well. 
They postulated that 60% of cisplatin were bound to GSH [35]. Goto et al. repeated the 
experiments using inside out vesicles prepared from A2780 and HCT-8 cells and cisplatin-
resistant variants. They identified the same platinum-GSH adduct described by Ishikawa and 
Ali-Osman finding higher excretion from resistant variants [37]. The experiments were 
performed in the early/mid 1990s and the MS applied did not give a spectrum in high 
resolution as it could be obtained nowadays. The authors assumed to have found a distinct 
adduct rather by mass than by isotope pattern or fragmentation. However, they confirmed the 
findings with NMR [35]. 
Investigating the incubation of aqueous extracts of cancer cells with cisplatin with the aid of 
2D nuclear magnetic resonance (NMR) spectroscopy Kasherman el al. observed that only up 
to 20% of cisplatin formed platinum-GSH adducts and that most of the platinum was found in 
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the high molecular mass fraction (> 3 kDa) indicating binding of platinum or platinum-GSH 
adducts to proteins [38]. In Escherichia coli, cisplatin was found to bind to carboxylato and 
hydroxyl as well as to methionyl-S atom binding sites of ribosomal proteins, DNA binding 
proteins and other proteins [120]. These data show that further research should not focus only 
on sulfhydryl groups but also on other nucleophilic binding sites of cellular structures such as 
proteins when investigating intracellular binding partners of platinum complexes.  
5.2 MRP-mediated efflux and platinum resistance 
5.2.1 Expression and localization of MRP2 
In in vitro experiments with human cancer cells MRP2 expression level was found to be 
associated with platinum resistance and also in vivo studies reflect a relationship between 
MRP2 expression and clinical outcome after platinum-containing chemotherapy [59-
61,63,68,69]. Hence experiments on MRP2 expression in the cell models investigated were 
performed. By SDS PAGE and protein immunoblotting MRP2 expression was detected in 
HCT-8 and HCT-8ox cells with a tendency towards a higher expression after oxaliplatin 
incubation in HCT-8 cells (not significant). MRP2 expression on protein level was negligible 
in A2780 cells and was low in A2780cis cells. It has to be noted that MRP2 levels detected 
were divergent from those reported by others, as expression of MRP2 was reported in A2780 
and A2780cis cells on mRNA and protein level [63,64]. Nevertheless, in the work of Hector 
et al. also low MRP2 protein levels were reported for A2780 cells and even lower for a 
variant resistant to oxaliplatin [106]. This divergence might be due to different cultivation 
conditions (cultivation duration, cell culture medium) and differences in the methods used for 
generating the resistant variants. 
In this project MRP2 expression was not determined on mRNA level but only on protein 
level. Generating data on mRNA expression would have further elucidated the role of MRP2 
and allowed comparison with results of others investigating mRNA levels. A 
posttranscriptional control of protein expression of MRP2 has been described and thus could 
be important for the understanding of MRP2 as MRP2 expression is regulated at several steps 
(translation, transcription, membrane removal and membrane reinsertion) [49,121]. 
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Surowiak et al. postulated that MRP2 expression in the nuclear membrane correlated with 
cellular resistance to cisplatin [64]. Using fluorescence microscopy, expression of MRP2 was 
illustrated but a nuclear expression was not shown in HCT-8 and HCT-8ox cells. Research 
findings suggest that MRP2 can be rapidly removed from the nuclear membrane or be 
inserted into canalicular membranes [121]. As no significant change in MRP2 protein 
expression was seen after addition of platinum complexes, MRP2 may have been inserted into 
membranes to a greater extent as response to addition of platinum complexes instead of being 
increasingly expressed. This effect, however, could not be confirmed in fluorescence 
microscopy experiments either.  
5.2.2 Effects of MRP modulators 
Platinum accumulation 
MRP modulators led to an increase in platinum accumulation in the cell lines with higher 
MRP2 expression (HCT-8 and HCT-8ox cells) but not in those with negligible or low MRP2 
expression (A2780 and A2780cis cells). Hence MRP-mediated efflux is likely to take place. 
Regarding platinum accumulation in HCT-8 and HCT-8ox cells upon oxaliplatin exposure, 
the effect of MRP modulators was significant with Gü83 [100 µM] but when ciclosporin 
[100 µM] and indometacin [200 µM] were applied it was only significant for ciclosporin in 
HCT-8 cells. Nevertheless, the tendency towards an increase in platinum accumulation was 
also seen for indometacin in HCT-8 and HCT-8ox cells. Considering the IC50 values 
described by Leyers et al. the chosen concentrations were far above the reported IC50 values 
of Gü83 and ciclosporin. The chosen concentration of indometacin was below the IC50 value 
for MRP2 and hence a higher concentration might have led to a significant effect [54]. The 
effect of indometacin and ciclosporin was not assessed over time, which probably would have 
provided more information than the investigation at only one time point. 
The effect of Gü83 on platinum accumulation was similar for cisplatin and oxaliplatin, 
supporting the findings of Wortelboer et al. suggesting that both platinum complexes are 
substrates of MRP1 and MRP2 [53]. As the modulator substances used modulate MRP1 and 
MRP2, it is not possible to distinguish between both transporters. The increase in platinum 
accumulation was comparable in the sensitive and resistant variant and thus MRP-mediated 
efflux does not necessarily contribute to resistance in HCT-8ox.  
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Regarding the platinum accumulation without any modulator, the acknowledged hypothesis 
that reduced cellular platinum accumulation is associated with resistance was confirmed, as 
higher platinum accumulation was found in the sensitive cells (A2780, HCT-8) compared to 
cells of the resistance variants (A2780cis, HCT-8ox) [5]. This difference was not seen when 
the platinum accumulation upon cisplatin exposure was investigated in HCT-8 and HCT-8ox 
cells although HCT-8ox cells were cross-resistant to cisplatin, suggesting that platinum 
accumulation can be but is not necessarily a predicting factor of resistance which also was 
reported by others [108]. 
The effect of MRP modulator Gü83 on platinum efflux was also addressed experimentally. 
According to the results, incubation with Gü83 did not significantly influence platinum efflux 
in HCT-8 and HCT-8ox cells. As platinum accumulation, which comprises platinum uptake 
and platinum efflux, was significantly increased by Gü83 and the substance was described to 
modulate platinum efflux, a difference in efflux is probable but the method used for assessing 
the efflux was possibly not sensitive enough to prove it. A longer incubation time and 
consequently a higher level of platinum accumulation might have generated a more distinct 
effect. In HCT-8 cells, however, results indicate a reduced efflux when Gü83 is 
co-administered at least in the first 10 min. 
DNA platination 
The observed increase in platinum accumulation after addition of Gü83 to oxaliplatin 
treatment of HCT-8 and HCT-8ox cells was accompanied by an increase in DNA platination. 
DNA platination was higher in HCT-8 compared to HCT-8ox cells and hence the results 
reproduce the lower DNA platination in oxaliplatin-resistant cells described by others [122]. 
The difference was not significant after 3 h but in the same cell models a significant 
difference was shown incubating cells with oxaliplatin over 4 h [70].  
When DNA platination was related to platinum accumulation it appeared that the increase of 
platinum accumulation achieved by Gü83was not associated with a proportional increase in 
DNA platination, indicating that DNA was not damaged as efficiently by a higher amount of 
intracellular oxaliplatin. This could have been due to increased detoxification or DNA repair. 
However, scatter was too high and the sample size too small to establish generalizations.  
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Comparative potency of MRP modulators 
Using the calcein assay the effect of modulator substances on calcein efflux and hence on 
efflux via MRP1, MRP2 and P-gp can be investigated. However, when performing the assay 
the effect of MRP1, MRP2 and P-gp cannot be distinguished [88]. In HCT-8 and HCT-8ox 
cells MRP2 expression was determined. MRP1 and P-gp expression was described for HCT-8 
in literature [123,124].  
Investigating the inhibitory effect of substances on calcein efflux, ciclosporin was associated 
with lowest IC50 values in HCT-8 and HCT-8ox cells. This finding is probably due to the fact 
that it is active in modulation of MRP1, MRP2 and P-gp. Gü83 as well as indometacin 
modulate MRP1 and MRP2 but not P-gp. Their respective IC50 values were different in 
HCT-8 compared with HCT-8ox cells, which cannot be explained in this place apart from 
inaccuracy as reflected by high experimental variation. IC50 values of indometacin were 
higher compared with Gü83 as already reported [54]. 
Coincubation with MRP modulators affected cellular platinum accumulation of cisplatin and 
oxaliplatin and hence it can be assumed that transport of cisplatin and oxaliplatin by MRP1 
and/or MRP2 takes place. As no effect on calcein efflux was seen in the calcein assay with 
various concentrations of oxaliplatin a modulation of MRP1-, MRP2- or P-gp-mediated efflux 
by oxaliplatin is not likely. 
Cytotoxicity 
As described above, Gü83 led to an increase of platinum accumulation and DNA platination 
after 3 h coincubation with oxaliplatin. Hence an increase in oxaliplatin cytotoxicity was 
expected when the impact of Gü83 on oxaliplatin cytotoxicity was investigated. But the 
opposite effect, as demonstrated by higher EC50 values for oxaliplatin in HCT-8 and HCT-8ox 
cells, was observed. Results indicate that the achieved increase in platinum accumulation and 
DNA platination by Gü83 is not helpful in overcoming oxaliplatin resistance or in sensitizing 
cells towards oxaliplatin. This paradox result suggests that an increased MRP-mediated efflux 
is a first defensive mechanism but is not decisive for long-term cytotoxicity.  
To understand why increased DNA platination does not necessarily lead to sensitization it has 
to be considered that the mechanism of action of platinum complexes involves more than the 
processes started by DNA platination. For cisplatin, involvement of ER and for oxaliplatin, 
involvement of mitochondria in apoptosis was shown in enucleated cells [125,126]. The 
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consequences of Gü83 co-incubationon on the effect of oxaliplatin on cellular structures apart 
from DNA were not assessed. But as Gü83 was not supportive in sensitizing cells, further 
cellular targets involved in oxaliplatin cytotoxicity were probably not affected. Another 
possible explanation for the unexpected result may be that MRP1 and MRP2 inhibition leads 
to increased cellular accumulation of oxaliplatin metabolites, such as mono-GSH adducts, 
which still bind to DNA but are not capable anymore to form inter- or intrastrand crosslinks 
and thus do not result in increased cytotoxicity.  
A limitation of the results is that the conditions of the MTT assay differed from the conditions 
used for measuring platinum accumulation and DNA platination. Whereas platinum 
accumulation and DNA platination were assessed up to 3 h of oxaliplatin incubation, the 
protocol of the MTT assay included an incubation period of 72 h. Thus, it is possible that the 
MRP inhibition is only effective during a relatively short incubation period. Modifications in 
the protocol of the MTT assay or further methods should be applied for confirming that MRP 
inhibition does not affect oxaliplatin cytotoxicity in the cells investigated. As a second assay 
for determination of cytotoxicity the adenosine triphosphate (ATP) assay could be used. By 
assessing the ATP content and thus cellular energy exchange, the ATP assay can detect 
cytotoxic effects already after short incubation periods [73]. 
5.3 Interaction between glutathione and MRP in platinum resistance 
An association of MRP-mediated efflux of oxaliplatin and GSH was not found in HCT-8 and 
HCT-8ox cells. MRP-mediated efflux of oxaliplatin was confirmed (see chapter 5.2.2) but as 
GSH depletion did not affect platinum accumulation (see chapter 5.1.3), GSH does not seem 
to play a role in MRP-mediated efflux of oxaliplatin. Whether the oxaliplatin-GSH adduct 
identified (see chapter 5.1.4) is intracellularly formed in HCT-8 and HCT-8ox cells cannot be 
answered by the results of this project. However, in view of the finding that GSH does not 
have a function in MRP-mediated efflux it is not likely that a large proportion of oxaliplatin is 
excreted in the form of oxaliplatin-GSH adducts. In summary, none of the potential ways of 
interaction of GSH, MRP and endo- or exogenous substances described in chapter 1.6 seems 
to be relevant in case of oxaliplatin. 
Nevertheless, a relationship between MRP and GSH is probable as genes coding for MRP and 
for proteins involved in GSH homeostasis are partially regulated by the same transcription 
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factors. AP-1 and Nrf2 are involved in GSH regulation (see chapter 5.1.2) but were also 
associated with MRP2 expression [110,112,121,127]. Hence both cellular mechanisms of 
defense can be activated by the same cellular signals. This connection, however, does not 
seem to be relevant for MRP-mediated efflux of oxaliplatin in HCT-8/HCT-8ox cells. 
5.4 Clinical relevance 
The results of the conducted in vitro experiments do not emphasize certain resistance 
mechanisms towards platinum complexes which could be therapeutically targeted. The effects 
of GSH depletion by BSO have been addressed in this project and an increase of oxaliplatin 
cytotoxicity was found. GSH depletion by BSO has also been and is currently investigated in 
clinical trials to improve the efficacy of melphalan, an alkylating chemotherapeutic agent, but 
there does not seem to be clinical research on co-administration of BSO and platinum 
complexes [128,129]. As described in chapter 1.4.2, instead of GSH depletion administration 
of GSH in addition to platinum-containing chemotherapy has been tested in clinical trials 
aiming to ameliorate toxicity. The results of this research project do not support the use of 
GSH as cytoprotectant as depletion of GSH was associated with sensitization towards 
oxaliplatin and thus an increase of GSH might be associated with decreased sensitivity. 
However, it has to be considered that intravenous administration of GSH does not necessarily 
cause increased GSH concentrations in patients’ tumor tissue.  
MRP modulation using Gü83 did not result in sensitization of HCT-8 or the oxaliplatin-
resistant variant HCT-8ox towards oxaliplatin. This finding is consistence with results from 
clinical trials aiming to overcome multidrug resistance (MDR) to cancer chemotherapy by 
co-administration of modulator substances. To date, the trials involving a greater subset of 
patients (≥ phase II) have not proven sufficient benefit in the treatment of solid tumors and 
addition of modulator substances to chemotherapy was often associated with severe adverse 
effects. Hence the respective drugs have not received marketing authorisation so far and are 
currently not therapeutically used. It has to be considered that trials were performed in heavily 
pre-treated patients with recurrent disease and that a clinical benefit is difficult to prove in this 
kind of study population. In Tab. 5-1 MDR modulators tested in clinical trials and their target 
protein are listed.  
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Tab. 5-1 MDR modulators added to cancer chemotherapy in clinical trials. 
Modulator Target protein Tumor Study types Reference 
Biricodar 
(VX-710) 
P-gp, MRP1, 
BCRP 
Small cell lung 
cancer,  
ovarian cancer 
Phase I, II [130,131] 
Valspodar 
(PSC 833) 
P-gp Breast cancer, 
ovarian cancer, 
multiple myeloma, 
peritoneal cancer 
Phase I to III [132-136] 
Dofequidar 
fumarate 
(MS-209) 
P-gp, MRP1 Breast cancer Phase I to III [137] 
Tariquidar 
(XR 9576) 
P-gp, BCRP Various solid 
tumors, among 
them are  
breast cancer,  
non-small cell lung 
cancer,  
ovarian cancer 
Phase I to III [129,138] 
As the use of modulator substances and GSH depletion do not seem to be succesful strategies 
in overcoming platinum resistance, another approach related to GSH and MRP-mediated 
efflux may be more promising. Recently, a clinical trial with navitoclax (ABT-263), an agent 
which mimics cellular Bcl-2 antagonists and inhibits anti-apoptotic activity of Bcl-2 and 
Bcl-xL, was conducted in patients suffering from solid tumors [139]. For navitoclax 
monotherapy there was no benefit in patients with relapsed small cell lung cancer [139]. 
However, as Bcl-2 overexpression might account for elevated GSH content in tumor cells 
(see 5.1.2) and as it was associated with platinum resistance, the co-administration of 
navitoclax and platinum-containing chemotherapy might be a beneficial perspective in the 
light of the results of this project [22]. In addition to approaches targeting single proteins 
biochemical modulation strategies, i.e. drugs that interfere with pathways mediating 
resistance, should be further explored to circumvent platinum resistance in in vitro 
experiments as well as in clinical trials [20].  
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6 CONCLUSIONS AND OUTLOOK 
This study provides a systematic approach to investigate the relevance of GSH and 
MRP-mediated efflux on platinum cytotoxicity and platinum resistance. In conclusion, the 
results suggest that intracellular GSH content is associated with oxaliplatin cytotoxicity but 
not with oxaliplatin resistance. Oxaliplatin or its metabolites were transported by MRP1 
and/or MRP2 but inhibition of MRP-mediated efflux did not result in an increase of 
sensitivity to oxaliplatin suggesting that MRP-mediated efflux does not influence cytotoxic 
activity of oxaliplatin. 
When investigating cellular GSH, total cellular GSH was determined in this study. Future 
research should focus on differentiation between unbound and protein-bound GSH, the ratio 
of GSH to its oxidized form, GSSG and of the distribution of GSH in cellular compartments 
as GSH might be an important factor regulating nuclear protein function in cell proliferation. 
Intracellular formation of platinum-GSH adducts is likely but the extent to which platinum 
complexes react with GSH, whether adducts are transported by MRP and the implications for 
cellular platinum resistance need to be further questioned. To address these issues 
sophisticated analytical methodology is required as cellular extracts or biologic samples 
should be analyzed directly to monitor the formation of adducts over time.  
The findings suggest that alterations in platinum accumulation and DNA platination assessed 
after only a few hours of incubation do not necessarily result in changes in sensitivity to 
platinum complexes determined after longer time intervals. Platinum resistance is not based 
on simple mechanisms and for its elucidation intracellular signal cascades need to be taken 
into consideration rather than single proteins. Future research needs to investigate the 
complex interactions between cellular signal cascades resulting in apoptosis or cell 
proliferation after incubation with platinum complexes in sensitive and platinum-resistant 
tumour cells. Here, the systematic analysis of changes in gene expression, gene transcription 
and protein expression after exposure of cells to platinum complexes would be valuable. For a 
comprehensive approach whole cells or even their interaction in a united cell 
structure/organism need to be considered. 
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7 SUMMARY 
Therapeutic resistance towards platinum complexes is a multicausal interaction of diverse 
mechanisms. This project aimed to reveal the role of GSH and MRP-mediated efflux. 
Elevated GSH content, formation of platinum-GSH adducts and their efflux via MRP2 has 
been suggested to be associated with platinum resistance in many cases. In this project the 
impact of GSH and MRP-mediated efflux was investigated in two human cancer cell lines and 
their cisplatin- or oxaliplatin-resistant variant. The experiments focused on the platinum 
complex oxaliplatin as there is only limited research on the contribution of GSH and 
MRP-mediated efflux to oxaliplatin resistance so far.  
The results of this project indicate that GSH is associated with oxaliplatin cytotoxicity but not 
with oxaliplatin resistance. Depletion of GSH resulted in an increase of sensitivity towards 
oxaliplatin but did not affect platinum accumulation in human tumor cells. However, GSH 
depletion did not overcome oxaliplatin resistance and also incubating cells with oxaliplatin 
did not result in alterations of GSH content. ESI-MS was applied as a method for detection 
and structural analysis of platinum-GSH adducts. Furthermore, chemical structures of one 
oxaliplatin-GSH and two cisplatin-GSH adducts could be identified. The formation of 
intracellular platinum-GSH adducts is probable but still has to be confirmed in human cancer 
cells.  
Platinum accumulation was found to be increased after combined incubation of oxaliplatin or 
cisplatin with MRP modulators in cells expressing detectable levels of MRP2. Thus an efflux 
of cisplatin and oxaliplatin via MRP in the cells investigated is likely. But as GSH depletion 
did not affect platinum accumulation, the efflux does not seem to depend on GSH. In the case 
of oxaliplatin, DNA platination was also assessed and augmented accumulation was 
associated with an increase of platinated DNA. Despite these findings, MRP modulator 
co-incubation did not result in sensitization towards oxaliplatin and hence a direct association 
of MRP-mediated efflux and platinum resistance could not be shown. Moreover, oxaliplatin 
itself did not modulate MRP1- and/or MRP2-mediated efflux. 
In summary, this project contributes to the knowledge of the relevance of GSH and 
MRP-mediated efflux in platinum resistance. Based on the results cellular GSH content is 
associated with oxaliplatin cytotoxicity but not with oxaliplatin resistance. Results also 
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suggest that oxaliplatin as well as cisplatin are likely to be transported by MRP1 and/or 
MRP2. However, MRP-mediated efflux does not seem to play a role in oxaliplatin resistance.  
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9 APPENDIX 
APPENDIX A 
Cytotoxicity 
Sensitivity of HCT-8 and HCT-8ox (A) and A2780 and A2780cis (B) cells towards cisplatin and 
oxaliplatin expressed as pEC50 investigated using an MTT-based cytotoxicity assay (results of single 
testing days, n = 3-11). 
A 
 
pEC50 B 
 
pEC50 
 Cisplatin Oxaliplatin  Cisplatin Oxaliplatin 
 HCT-8 5.13 5.43  A2780 5.57 6.08 
  5.07 5.66   5.36 5.56 
  4.94 5.61   5.56 6.45 
   5.87   5.63  
   5.63   5.58  
   5.22   5.63  
   5.51   5.94  
   5.75   5.76  
   5.44   6.03  
   5.29   6.01  
   5.73   5.60  
 HCT-8ox 4.52 4.25  A2780cis 4.80 5.53 
  4.57 4.44   4.91 5.16 
  4.81 4.60   4.89 5.61 
   4.51   4.87  
   4.36   5.20  
   4.55     
   4.52 
   4.19    
   4.21 
   4.56 
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APPENDIX B 
GSH in platinum resistance 
B1 GSH assay validation 
Within-day accuracy and precision of six runs (SD = standard deviation, RSD = relative standard 
deviation, RE = relative error). 
 GSH content [µM] 
3 12 18 
Run 1 3.18 11.77 18.78 
Run 2 3.17 13.52 19.92 
Run 3 3.08 11.52 16.57 
Run 4 3.01 12.80 16.60 
Run 5 3.43 13.04 19.36 
Run 6 2.89 13.80 20.19 
Mean  3.13 12.74 18.57 
SD  0.18 0.92 1.61 
RSD [%]  5.87 7.24 8.68 
RE [%]  +4.22 +6.18 +3.17 
Between-day accuracy and precision comparing the results of five different days (SD = standard 
deviation, RSD = relative standard deviation, RE = relative error). 
 GSH content [µM] 
3 12 18 
Day 1 3.08 12.67 18.27 
Day 2 2.93 10.92 15.95 
Day 3 3.01 11.93 18.18 
Day 4 3.18 11.77 18.78 
Day 5 3.03 12.30 18.21 
Mean  3.05 11.92 17.88 
SD  0.09 0.66 1.11 
RSD [%]  3.03 5.52 6.18 
RE [%]  +1.53 -0.68 -0.68 
Recovery of a low, medium and high GSH content tested (n = 3). 
GSH content [µM] Recovery [%] Mean [%] (SD) 
0.5 57.4 54.2 32.3 48.0 (13.6) 
3.3 48.5 43.7 35.8 42.7 (6.4) 
7.5 53.0 46.9 38.2 46.0 (7.4) 
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Linearity of the fluorescence signal of the GSH-NDA adduct after isolation and lysis of different 
numbers of cells (r = correlation coefficient, df = degrees of freedom (= number of x-values – 2); 
n = 2-3). 
A2780 
 Slope Intercept df r 
 2.181 +0.408 2 0.9683 
 2.534 -0.340 2 0.9995 
 1.291 -1.173 2 0.9135 
   
A2780cis 
 Slope Intercept df r 
 2.916 -0.220 2 0.9993 
 2.332 -1.036 2 0.9920 
 
HCT-8 
 Slope Intercept df r 
 5.103 0.000 1 0.9999 
 5.230 -0.065 1 0.9989 
   
HCT-8ox 
 Slope Intercept df r 
 14.52 -0.326 1 0.9992 
 16.20 -0393 1 0.9981 
Calibration curves from five testing days (SD = standard deviation, RSD = relative standard deviation, 
RE = relative error). 
 Concentration [µM]  
1 2 5 10 15 20 r 
Day 1 1.00 1.97 5.02 10.41 14.83 19.54 0.9998 
Day 2 0.95 2.19 5.13 10.82 13.45 19.10 0.9976 
Day 3 1.00 1.98 5.28 10.20 14.38 19.60 0.9995 
Day 4 1.01 1.97 4.85 10.11 15.11 20.31 0.9998 
Day 5 1.01 1.97 5.07 10.20 14.75 19.87 0.9998 
Mean  0.99 2.02 5.07 10.35 14.50 19.68 0.9993 
SD  0.03 0.10 0.16 0.29 0.64 0.45 0.001 
RSD [%]  2.53 4.83 3.10 2.76 4.44 2.27  
RE [%]  -0.60 +0.80 +1.40 +3.48 -3.31 -1.58  
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Comparison of unweighted and weighted calibration of the calibration curves of five testing days 
(RSS = residual sum of squares, r = correlation coefficient). 
Weighting Unweighted  1/x  1/x² 
RSS r  RSS r  RSS r 
Day 1 0.293 0.9998  0.089 0.9998  0.012 0.9998 
Day 2 2.230 0.9977  0.128 0.9981  0.145 0.9976 
Day 3 0.329 0.9997  0.137 0.9997  0.026 0.9995 
Day 4 0.036 0.9999  0.025 0.9999  0.008 0.9998 
Day 5 0.093 0.9999  0.031 0.9999  0.006 0.9999 
Mean  0.596 0.9994  0.082 0.9995  0.039 0.9993 
Sum  2.981 -  0.411 -  0.196 - 
B2 Cellular GSH content 
Cellular GSH content related to the protein content [µM/g] in untreated cells; results from three 
independent experiments (n = 3). 
Cell line HCT-8 HCT-8ox A2780 A2780cis 
 30.9 45.6 18.0 45.5 
 68.2 55.7 23.6 58.8 
 54.8 52.4 18.8 54.6 
Mean 51.3 51.3 21.2 53.0 
SD 18.9 5.1 3.4 6.8 
Cellular GSH content related to the protein content relative to baseline value (0 h = 100%) [%] upon 
incubation with 100 nM oxaliplatin (HCT-8, HCT-8ox) or 100 nM cisplatin (A2780, A2780cis) 
(mean (SD), n = 3). 
Time HCT-8 HCT-8ox A2780 A2780cis 
[h] +oxaliplatin control +oxaliplatin control +cisplatin control +cisplatin control 
4 101.2 
(29.8) 
95.6 
(44.6) 
111.2 
(15.6) 
90.4 
(19.2) 
128.5 
(30.2) 
112.8 
(13.5) 
110.1 
(12.7) 
99.6 
(16.0) 
8 111.1 
(20.2) 
91.0 
(22.8) 
91.7 
(18.0) 
87.0 
(32.1) 
123.6 
(36.7) 
110.0 
(35.2) 
98.4 
(11.0) 
92.9 
(3.1) 
12 100.5 
(9.3) 
98.8 
(28.6) 
98.4 
(39.5) 
94.5 
(38.1) 
132.7 
(30.1) 
105.3 
(4.1) 
88.3 
(5.9) 
99.2 
(15.1) 
24 75.0 
(41.3) 
75.8 
(42.2) 
80.5 
(15.0) 
95.4 
(31.2) 
100.6 
(46,4) 
98.9 
(34.9) 
79.0 
(11.0) 
86.1 
(4.8) 
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Results of two-way ANOVA analysis of influence of time and cisplatin or oxaliplatin treatment on 
cellular GSH content. 
 HCT-8 HCT-8ox 
Variable % of total variation p value % of total variation p value 
Oxaliplatin [100nM] 1.07 0.6159 0.44 0.7527 
Time [h] 14.45 0.4942 5.99 0.8442 
Interaction 2.23 0.9673 9.80 0.8118 
 A2780 A2780cis 
 % of total variation p value % of total variation p value 
Cisplatin [100nM] 5.03 0.2705 0.03 0.9162 
Time [h] 12.91 0.5254 41.36 0.0104 
Interaction 3.70 0.9146 11.55 0.3308 
B3 GSH depletion 
Impact of GSH depletion (50 µM BSO) on oxaliplatin cytotoxicity expressed as pEC50 determined by 
the MTT assay (n = 4-5). 
 HCT-8 HCT-8ox 
 +BSO control +BSO control 
 5.877 5.80 4.30 4.10 
 5.883 5.71 4.43 4.47 
 5.956 5.78 4.51 4.17 
 5.232 5.00 4.53 4.58 
 - - 4.57 4.51 
Mean 5.74 5.57 4.47 4.37 
SEM 0.17 0.19 0.05 0.10 
Cellular platinum accumulation related to protein content [ng/µg] after 2 h incubation with 100 µM 
oxaliplatin with or without 12 h preincubation with 100 µM BSO, results from five independent 
experiments. 
 HCT-8 HCT-8ox 
 +BSO control +BSO control 
 0.40 0.42 0.16 0,20 
 0.56 0.60 0.44 0.26 
 0.31 0.31 0.24 0.26 
 0.32 0.32 0.22 0.28 
 0.39 0.48 0.24 0.28 
Mean 0.40 0.43 0.25 0.26 
SD 0.10 0.12 0.03 0.11 
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APPENDIX C 
C1 Experiments identifying platinum-GSH adducts described in literature 
Author Experimental setting Analytical 
method 
Adducts 
Appleton et al. [90] Cisplatin diaqua complex 
(0.42 mM) + GSH 
(0.34 mM) 
15
N NMR Adduct 
Bernareggi et al. [91] Cisplatin (3.33 mM) + GSH 
(3.33 mM) in buffer 37 °C, 
1 h 
LC-MS Two adducts 
Berners-Price and 
Kuchel [92] 
Cisplatin (50 mM) + GSH 
(150 mM) in buffer,23 °C, 
7 h 
Diverse NMR Macromolecular 
polymer with a 1:2 
Pt:GSH stoichiometry, 
adducts 
Dedon and Borch [93] Cisplatin (3mM) + GSH (6 
to 2 mM), 37 °C, several 
days of incubation, in H20 
und 0.9% NaCl 
1
H NMR 
 
Macromolecular adduct 
with a 1:2 Pt:GSH 
stoichiometry and one 
adduct 
Goto et al. [37] Cisplatin (1.67 mM) + GSH 
(3.33 mM) in PBS, 24 °C, 
48 h; HCT-8 and A2780 
cells incubated with 3 µM 
cisplatin 
HPLC, AAS One adduct, also 
detected in cells 
Heudi et al. [94] Cisplatin (0.9 mM) + GSH 
(0.9 mM), 37 °C, 24h  
LC-ESI-MS Eleven different 
adducts, only two of 
those left after 24 h  
Ishikawa and 
Ali-Osman [35] 
Cisplatin (1.67 mM) + GSH 
(3.33 mM) in PBS, 37 °C, 
48 h; leukemia cells 
incubated with 20 µM 
cisplatin 
HPLC, 
MALDI, 
1
H NMR 
One adduct, also 
detected in cells 
Odenheimer et al. [95] Cisplatin (0.33 mM) + GSH 
(0,67 mM) in 0.9% NaCl, 
37 °C, 4-5 days 
IR One adduct 
Peklak-Scott et al. [41] Cisplatin (1 mM) + GSH 
(2 mM) 25 °C, up to 60 min 
HPLC, ESI-
MS 
Two adducts 
Townsend et al. [96] Cisplatin (3.33 mM) + GSH 
(3.3 mM) in buffer, 37 °C 
LC-MS Two adducts 
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Author Experimental setting Analytical 
method 
Adducts 
Zhao et al. [140] Cisplatin (0.1 mM) + GSH 
(2 mM) in saline solution, 
37 °C, 4 h 
LC-ICP-MS Two adducts, no 
structure suggested 
Luo et al. [97] Oxaliplatin (50 µM) in 
heparinized rat blood  
HPLC Suggestion of two 
adducts 
AAS: Atomic absorption spectroscopy, HPLC: high-performance liquid chromatography, ICP: inductively 
coupled plasma, IR: infrared spectrometry, LC: liquid chromatography, MALDI: matrix-assisted laser 
desorption/ionization, MS: mass spectrometry, NMR: nuclear magnetic resonance.  
C2 Chemical structure of cisplatin- and oxaliplatin-GSH adducts described 
in literature 
 Chemical structure Molar mass Literature 
1 
 
570.9 g/mol Bernareggi et al., 
1995 [91]  
Townsend et al., 
2003 [96] 
Peklak-Scott et al., 
2008 [41] 
2 
 
534.5 g/mol Berners-Price and 
Kuchel, 1990 [92] 
3 
 
807.6 g/mol Dedon and Borch, 
1987 [93] Odenheimer, 
1982 [95] 
trans 
 
Ishikawa and 
Ali-Osman, 1993 [35] 
cis 
HOOC
NH
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 Chemical structure Molar mass Literature 
4 
 
843.6 g/mol Berners-Price and 
Kuchel, 1990 [92] 
(macromolecular 
polymer) 
5 
 
835.5 g/mol Appleton et al., 
1998 [90], 
Bernareggi et al., 
1995 [91], 
Peklak-Scott et al., 
2008 [41] 
6 
 
835.5 g/mol Townsend et al., 
2003 [96] 
Heudi et al., 2001 [94] 
7 
 
798.64 g/mol Heudi et al., 2001 [94] 
N
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 Chemical structure Molar mass Literature 
8 
 
1070.9 g/mol Appleton et al., 
1998 [90] 
 
9 
 
614 g/mol Luo et al., 1999 [97] 
10 
 
1037 g/mol Luo et al., 1999 [97] 
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C3 Isotope pattern for adduct 1 created in silico using an isotope 
distribution calculator 
Isotope distribution calculator available at www.sisweb.com/mstools/isotope.htm. 
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APPENDIX D 
MRP2 in platinum resistance 
D1 MRP2 expression 
Expression of MRP2 normalized to β-actin in untreated cells and after treatment with 10 µM 
oxaliplatin for 12 h (mean ± SD, n = 2-6). 
Cell line Mean SD n 
HCT-8 1.06 0.57 5 
HCT-8 + oxaliplatin 1.91 0.70 3 
HCT-8ox 0.97 0.32 6 
HCT-8ox+ oxaliplatin 1.12 0.40 3 
A2780 n. d. - 2 
A2780cis 0.26 0.32 3 
 n. d.: not detected 
D2 Effects of MRP modulators on platinum accumulation and DNA 
platination 
Cellular platinum accumulation related to protein content [ng/µg] after 2 h incubation with different 
concentrations of Gü83 and 100 µM oxaliplatin in HCT-8 cells (results of individual testing days, 
n = 1-5). 
log [Gü83] HCT-8  Mean SD 
-7 0.38 0.32 0.39 0.34 -  0.36 0.03 
-5 0.26 0.46 - - -  0.36 0.14 
-4.7 0.27 0.35 - - -  0.30 0.05 
-4.4 0.50 0.25 0.47 0.78 0.53  0.51 0.19 
-4 0.91 0.65 0.82 0.69 -  0.77 0.12 
-3.7 2.00 1.62 - - -  1.81 0.27 
Cellular platinum accumulation related to protein content [ng/µg] after 2 h incubation with different 
concentrations of Gü83 and 100 µM oxaliplatin in HCT-8ox cells (results of individual testing days, 
n = 1-5). 
log [Gü83] HCT-8ox  Mean SD 
-7 0.16 0.20 0.12 0.20 -  0.17 0.04 
-5 0.10 - - - -  - - 
-4.7 0.09 - - - -  - - 
-4.4 0.18 0.08 0.42 0.52 -  0.30 0.20 
-4 0.59 1.01 0.95  -  0.85 0.23 
-3.7 1.22 - - - -  - - 
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Cellular platinum accumulation related to protein content [ng/µg] after incubation with DMSO or 
100 µM Gü83 in DMSO and 100 µM oxaliplatin (mean (SD), n = 3). 
 HCT-8 HCT-8ox 
Time [h] +Gü83 control +Gü83 control 
0.5 0.13 (0.03) 0.10 (0.04) 0.04 (0.01) 0.09 (0.06) 
1 0.21 (0.07) 0.15 (0.03) 0.07 (0.02) 0.09 (0.01) 
2 0.54 (0.07) 0.34 (0.22) 0.17 (0.05) 0.25 (0.06) 
3 1.11 (0.13) 0.48 (0.05) 0.25 (0.20) 0.70 (0.06) 
Results of two-way ANOVA analysis of influence of time and Gü83 on platinum accumulation. 
 HCT-8 HCT-8ox 
Variable % of total variation p value % of total variation p value 
Gü83 [100µM] 14.91 0.0002 15.78 < 0.0001 
Time [h] 64.54 < 0.0001 65.90 < 0.0001 
Interaction 17.26 0.0013 15.23 0.0011 
Cellular platinum accumulation related to protein content [ng/µg] after 2 h incubation with 100 µM 
Gü83 and 100 µM cisplatin (results of individual testing days, n = 4-5). 
 HCT-8 HCT-8ox 
 +Gü83 control +Gü83 control 
 1.56 2.33 1.49 2.21 
 1.58 2.01 1.64 1.03 
 1.10 1.77 0.61 1.02 
 1.13 2.63 1.22 2.11 
 1.33 - 0.90 1.42 
Mean 1.34 2.18 1.17 1.56 
SD 0.23 0.38 0.42 0.57 
Cellular platinum accumulation related to protein content [ng/µg] after 2 h incubation with 100 µM 
Gü83 and 100 µM cisplatin (mean ± SD, n = 3). 
 A2780 A2780cis 
 +Gü83 control +Gü83 control 
 1.27 1.71 0.92 0.82 
 1.87 1.89 0.75 0.56 
 1.12 1.73 0.78 0.68 
Mean 1.42 1.78 0.81 0.69 
SD 0.39 0.09 0.09 0.13 
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Platinum efflux illustrated as platinum content related to protein content [ng/µg] after 2 h incubation 
with 100 µM oxaliplatin without or with 100 µM Gü83 over time after replacing cell culture medium 
(mean (SD), n = 3). 
Time with 
platinum free 
medium [min] 
HCT-8 HCT-8ox 
+Gü83 control +Gü83 control 
0 0.76 (0.06) 0.83 (0.01) 0.18 (0.04) 0.15 (0.04) 
2 0.59 (0.02) 0.48 (0.01) 0.11 (0.03) 0.11 (0.05) 
5 0.55 (0.01) 0.49 (0.12) 0.12 (0.04) 0.12 (0.02) 
10 0.50 (0.01) 0.47 (0.05) 0.13 (0.08) 0.16 (0.06) 
60 0.40 (0.10) 0.44 (0.15) 0.12 (0.06) 0.10 (0.05) 
Results of two-way ANOVA analysis of influence of time and Gü83 on platinum efflux. 
 HCT-8 HCT-8ox 
Variable % of total variation p value % of total variation p value 
Gü83 [100µM] 0.32 0.6402 0.27 0.8668 
Time [h] 65.71 < 0.0001 23.53 0.1446 
Interaction 5.27 0.4712 3.87 0.7694 
DNA platination [platinum atoms/106 nucleotides] (A) and platinum accumulation [ng/µg] (B) after 
3 h incubation with 200 µM Gü83 and 100 µM oxaliplatin (results of individual testing days, n = 3). 
A   
 HCT-8 HCT-8ox 
 +Gü83 control +Gü83 control 
 67.4 19.8 69.7 16.6 
 52.1 22.4 24.1 17.0 
 97.4 22.8 49.4 8.7 
Mean 72.3 20.7 47.7 14.1 
SD 23..0 3.3 22.8 4.7 
   
B   
 HCT-8 HCT-8ox 
 +Gü83 control +Gü83 control 
 5.36 0.64 3.20 0.47 
 5.30 0.85 1.41 0.63 
 6.86 0.35 4.42 0.35 
Mean 5.84 0.61 3.01 0.48 
SD 0.88 0.25 1.51 0.14 
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Cellular platinum accumulation related to protein content [ng/µg] after 2 h incubation with 200 µM 
indometacin and 100 µM oxaliplatin (results of individual testing days, n = 3). 
 HCT-8 HCT-8ox 
 +indometacin control +indometacin control 
 0.68 0.42 0.56 0.15 
 0.43 0.29 0.40 0.13 
 0.88 0.45 0.83 0.22 
Mean 0.66 0.39 0.60 0.17 
SD 0.23 0.09 0.22 0.05 
Cellular platinum accumulation related to protein content [ng/µg] after 2 h incubation with 100 µM 
ciclosporin and 100 µM oxaliplatin (results of individual testing days, n = 3). 
 HCT-8 HCT-8ox 
 +ciclosporin control +ciclosporin control 
 1.31 0.94 0.75 0.59 
 1.41 0.98 0.43 0.61 
 1.31 0.94 0.75 0.59 
Mean 1.34 0.95 0.64 0.60 
SD 0.06 0.02 0.18 0.02 
D3 Comparative potency of MRP modulators 
pIC50 of the MRP modulators derived from calcein efflux experiments (results of individual testing 
days, n = 3). 
 
pIC50  
HCT-8 HCT-8ox 
Gü83 4.75 5.05 
5.88 4.39 
5.02 4.82 
Indometacin 4.35 4.01 
3.60 4.26 
3.09 3.72 
Ciclosporin  5.24 5.50 
6.11 6.03 
5.99 5.72 
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D4 Effect of Gü83 on oxaliplatin cytotoxicity 
pEC50 of oxaliplatin with or without coincubation with 100 µM Gü83 (results of individual testing 
days, n = 4). 
 HCT-8 HCT-8ox 
 +Gü83 control +Gü83 control 
 5.42 5.45 5.20 4.15 
 5.49 5.59 4.66 4.88 
 5.41 5.54 5.51 4.72 
 5.08 5.21 4.13 4.63 
Mean 5.35 5.45 4.62 4.84 
SEM 0.09 0.08 0.22 0.11 
 
